Stockwinners Market Radar for March 19, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:56 EDT BBVA to modify branch service to 'drive-thrus' - BBVA USA announced that it would be closing most of its 637 branch lobbies and instead serving customers through its drive-thrus as a proactive measure to protect the health and well-being of customers, employees and communities, as well as do its part to limit the spread of the coronavirus COVID-19. Effective March 20 the majority of BBVA USA branches will move to drive-thru only, while some locations without drive-thrus or in close proximity to branches with active drive-thrus will be closed. Five percent of branches will operate with limited lobby hours three days a week. These are branches without a drive-thru and are located more than 10 miles from the next closest BBVA location. Starting March 21, all branches will be closed on Saturdays until further notice.

20:32 EDT Sysco to donate 2.5M meals over next 4 weeks - Sysco announced it will donate 2.5 million meals over the next four weeks as part of its community response strategy to the COVID-19 pandemic. The company is closely collaborating with an array of critical stakeholders, from suppliers, customers, government entities and the non-profit sector, to address food insecurity and the added constraints on the food bank system during these challenging times. Sysco's response strategy is focused on working with its key national partners, Feeding America in the U.S. and Second Harvest in Canada, in support of food redistribution efforts across the supply chain in North America. The strategy has a four-pronged approach focused around product donations, delivery to foodbanks, providing additional storage and supporting development of a mobile distribution platform.

20:14 EDT Nexstar CEO sells 7K shares of common stock - In a regulatory filing, Nexstar disclosed that its CEO Perry Sook sold 7K shares of common stock on March 17th in a total transaction size of $469K.

19:59 EDT Walmart announces $550M in bonuses to hourly associates - Walmart announced plans to provide a special cash bonus for hourly associates for their hard work and dedication to serving customers in a time of an unprecedented national health crisis. The bonus is for all U.S. hourly associates in stores, clubs, supply chain and offices. The bonus will be $300 for full-time hourly associates and $150 for part-time hourly associates and will add up to more than $365 million. Every hourly associate employed by the company as of March 1 will qualify, and it will pay out on April 2. In addition to that special bonus for hourly associates, the company will accelerate the next scheduled quarterly bonus for store, club and supply chain associates a month early. When it pays out in late April, it will help provide more cash in hand for associates sooner. The company will pay those bonuses as if the company achieved its first quarter plan. At the regularly scheduled time for bonus payout in May, that amount may increase for associates based on performance. In no case will an eligible associate receive less than the first quarter plan bonus payment. The early payout will add up to $180 million. Overall, it amounts to nearly $550 million going into associates' pockets and the economy at this important time.

19:50 EDT Cannes Film Festival postponed amid COVID-19 concerns - The Cannes International Film Festival said that the event cannot be held on the scheduled dates, from May 12 to 23. Several options are considered in order to preserve its running, the main one being a simple postponement, in Cannes, until the end of June-beginning of July, 2020. "At this time of global health crisis, our thoughts go to the victims of the COVID-19 and we express our solidarity with all of those who are fighting the disease," the organization said. Publicly traded companies in filmmaking include Disney (DIS), Comcast (CMCSA), ViacomCBS (VIAC), AT&T (T), Lionsgate (LGF.A, LGF.B), and Sony (SNE). Reference Link

18:51 EDT Danaher sees GE BioPharma deal being completed on March 31, 2020 - Danaher Corporation (DHR) announced that the U.S. Federal Trade Commission has accepted the proposed consent order in connection with Danaher's definitive agreement with General Electric Company (GE) to acquire the Biopharma business of GE Life Sciences. The acceptance by the FTC satisfies all required antitrust clearances needed to be obtained for the acquisition of GE Biopharma by Danaher. In addition to the FTC, the transaction has also been cleared by the European Commission and the Brazilian, Chinese, Israeli, Japanese, Korean and Russian antitrust authorities. The closing of the acquisition remains subject to other customary closing conditions set forth in the purchase agreement. Danaher currently expects that the acquisition will be completed on March 31, 2020.

18:28 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Crowdstrike (CRWD) up 19.9%... Scholastic (SCHL) up 1.8%. ALSO HIGHER: Rand Capital (RAND) up 154% after announcing its Rheonix developing COVID-19 assay... United Airlines (UAL) up 3.4% after Apollo reportedly buys part of UA's loan. DOWN AFTER EARNINGS: Ollie's Bargain (OLLI) down 7.4%. ALSO LOWER: Tesla (TSLA) down 5.7% after suspending production at Fremont... Kohls (KSS) down 3.1% after withdrawing guidance, closing stores... Bed Bath Beyond (BBBY) down 2.0% after announcing over 50% of all stores closing... Yelp (YELP) down 1.3% after withdrawing guidance. Movers as of 18:15ET.

18:11 EDT Two Harbors estimates book value down about 16% in Q1 - Two Harbors Investment has provided the following updates with respect to its business, through the close of business on March 19. "We estimate that our book value is down approximately 16% in the first quarter, through March 17, 2020. We continue to focus on raising excess liquidity and reducing leverage in our portfolio. We are actively managing interest rate risk in our portfolio. The markets are extremely volatile and asset spreads in Agency RMBS and legacy non-Agency RMBS have experienced material widening. The repo markets are continuing to function, albeit at wider levels. We expect to make an announcement regarding common and preferred dividends the week of March 23, 2020." "We are witnessing unprecedented market conditions stemming from the global COVID-19 pandemic. In light of this, the Board of Directors and management have determined that it is in the best interests of stockholders to delay any decision about our first quarter dividend declarations," stated Thomas Siering, Two Harbors' President and CEO. "We believe this is a prudent step in managing the company through a challenging and dynamic economic environment and is consistent with our goal of ensuring that we take steps to preserve long-term stockholder value."

17:57 EDT FTC imposes conditions on Danaher's acquisition of GE Biopharma - Danaher (DHR) has agreed to divest assets to settle Federal Trade Commission charges that its proposed $21.4B acquisition of General Electric's (GE) biopharmaceutical business, GE Biopharma, would violate federal antitrust law. The FTC alleges that the proposed acquisition would substantially lessen competition in the United States, and potentially the rest of the world, in highly concentrated product markets for ten products that companies use to manufacture biopharmaceutical drugs. Danaher will divest to Sartorius AG all rights and assets to research, develop, manufacture, market, and sell these products. Based in Germany, Sartorius provides bioprocessing equipment and other products to the life sciences industry. Reference Link

17:46 EDT Senate Republicans want $12,00 in COVID-19 cash payments , The Hill says - Senate Republicans are talking about giving Americans $1,200 in direct cash to bolster them "as part of a mammoth stimulus package, but the idea has sparked fierce division within the caucus," reports The Hill. "As part of a plan discussed during a closed-door caucus meeting on Thursday, checks would go individuals who make up to $75,000. After that the amount of assistance would be scaled down until it is phased out completely at $95,000, according to Sen. Kevin Cramer," added The Hill. Reference Link

17:41 EDT Carnival says COVID-19 to impact to be materially negative - For the first half of 2021, booking volumes since the Corporation's last conference call in mid-December through March 1, 2020,have been running slightly higher than the prior year. Also for the first half of 2021 and during the two weeks ended March 15, 2020, the Corporation booked 546,000 Occupied Lower Berth Days, OLBD, albeit considerably behind the prior year pace. As of March 15, cumulative advanced bookings for the first half of 2021, are slightly lower than the prior year. The Corporation previously announced a voluntary, temporary pause of its global fleet operations across all brands. The Corporation believes the ongoing effects of COVID-19 on its operations and global bookings will have a material negative impact on its financial results and liquidity. The Corporation also believes the effects of COVID-19 on the shipyards where its ships are under construction, will result in a delay in ship deliveries. The corporation is taking additional actions to improve its liquidity, including capital expenditure and expense reductions, and pursuing additional financing. Given the uncertainty of the situation, the Corporation is currently unable to provide an earnings forecast, however it expects a net loss on both a U.S. GAAP and adjusted basis for the fiscal year ending November 30, 2020.

17:35 EDT Aflac to acquire Zurich North America's Group Benefits business - Aflac's insurance subsidiaries American Family Life Assurance of Columbus and American Family Life Assurance of New York have entered into a definitive agreement to acquire Zurich North America's U.S. Corporate Life and Pensions - Group Benefits - business, which consists of group life, disability and absence management products. Aflac of Columbus and Aflac of New York will reinsure on an indemnity basis Zurich North America's U.S. in-force group life and disability policies with annualized earned premium of approximately $115M. Aflac will also acquire assets needed to support the group life and disability business, along with an absence management platform. Subject to customary closing conditions, the transaction is expected to close in the second half of 2020. It is anticipated that Zurich North America employees dedicated to the U.S. group life and disability business will transfer to Aflac. In addition, Aflac and Zurich have entered into an agreement with Benefit Harbor LP to transfer the assets and employees of Benefit Harbor Insurance Services, the outsourced platform supporting the group life and disability business of Zurich North America, to Aflac. No changes are expected in the location of where business activities reside today. Aflac expects the acquisition and associated growth expenses to be dilutive to 2020 adjusted EPS in 2c-3c. Aflac further expects modest run-rate dilution over the near-term as it continues to expand the platform.

17:33 EDT Kirkland's to temporarily close 424 stores due to coronavirus - Kirkland's announced that in response to the increased impact from the novel coronavirus it is closing its 424 stores across the country at 6 p.m. local time on March 19. The company plans to follow the guidance of the Centers for Disease Control and Prevention, as well as local and state government officials, and will reopen its stores when there are satisfactory assurances to do so. CEO Woodward noted, "As we assess the impact of necessary safety precautions, we are also aggressively managing our costs and infrastructure and supporting the continued growth in our e-commerce sales, which will remain open for home delivery. Separately, at the beginning of this week, we drew down $40 million of our $75 million revolving credit facility, which, when combined with approximately $12 million in cash, provides us approximately $52 million in cash."

17:29 EDT Boeing announces Nikki Haley resigns from board of directors - On March 16, Nikki Haley informed The Boeing Company of her decision to resign from the Board of Directors effective immediately. Ambassador Haley served on the Finance and Audit Committees. She joined the Board on April 29, 2019. A variety of approaches are currently under discussion among policymakers in the administration and Congress, as well as the private sector, to address the near-term liquidity needs of the aerospace, travel, and other sectors affected by the current COVID-19 crisis. The company is participating in those discussions and has informed the Board about the options currently being considered. Ambassador Haley informed the company that, as a matter of philosophical principle, she does not believe that the company should seek support from the Federal Government, and therefore decided to resign from the Board.

17:23 EDT Bed Bath & Beyond to temporarily close over 50% of stores in U.S., Canada - Bed Bath & Beyond announced that it would temporarily close over 50% of its stores across all its banners, within the United States and Canada, to help reduce the spread of the novel coronavirus. This includes the majority of its core, Bed Bath & Beyond retail stores. Subject to state and local regulations, the company will continue to operate stores which sell health care, personal care, infant care, cleaning supplies, or food and beverages, to provide customers with the essential products they need. Mark Tritton, President & CEO, said, "In this time of great uncertainty, our first priority is the welfare of our customers and associates. We are therefore taking this decisive action to help keep our communities safe, while continuing to serve our loyal customers with the essential cleaning, health and personal care products that they and their families need at this time. We will continue to adapt and be responsive as our customer needs change, and in line with public health guidance and regulations." As of the morning of Friday, March 20, the company will take the following actions: Closing around 800 Bed Bath & Beyond store locations until April 3, 2020, that do not have a health and personal care department. Associates will be provided with pay and applicable benefits during this period. Operating approximately 700 essential stores, including the company's buybuy BABY, Harmon and other concepts, as well as any Bed Bath & Beyond stores that do have a health and personal care department. To the extent state and local regulations permit, these stores will operate under limited hours to provide essential products, such as supplies for infants and babies, health and personal care, cleaning products, food and beverages. Continuing our commitment to implement a number of policies to help associates and customers remain safe and healthy. This includes enhanced cleaning routines across stores, frequent cleaning of high-touch surfaces, practicing social distancing while in-store, and ensuring adherence to public health guidelines. Enhancing e-commerce and distribution capabilities to serve more customers in their homes across all concept brands. This includes increasing local fulfillment capabilities by utilizing some stores being temporarily closed to the public across the U.S. and Canada, to serve customers in their homes across brands. As this situation continues to evolve, the Company is monitoring guidance provided by multiple local, state, federal, and global public health entities and stands ready to implement immediate changes, as needed.

17:19 EDT Bank of America announces further support for consumer, small business clients - Bank of America today announced additional support for its 66 million Consumer and Small Business clients in response to the unprecedented challenges of the coronavirus. The company is offering assistance to clients through its Client Assistance Program and continuing to provide access to the important financial services on which these clients rely. Working on a case-by-case basis, as we've done in many other situations including the government shutdown and natural disasters, Bank of America's additional assistance for clients impacted by the coronavirus includes: Consumer and Small Business deposit accounts: clients can request refunds including overdraft fees, non-sufficient funds fees, and monthly maintenance fees. Consumer and Small Business credit cards: clients can request to defer payments, refunds on late fees. Small business loans: clients can request to defer payments, refunds on late fees. Auto loans: clients can request to defer payments, with payments added to the end of the loan. Mortgages and home equity: clients can request to defer payments, with payments added to the end of the loan. In all of these instances, there will be no negative credit bureau reporting for up-to-date clients. We have also paused foreclosure sales, evictions and repossessions.

17:09 EDT Kadant says bookings performance to date ahead of forecast - Kadant CEO Jeffrey Powell says: "In recent weeks, the public health response to the COVID-19 outbreak has significantly escalated, and our thoughts remain with the healthcare workers, individuals, and communities most deeply affected by the disease. As we continue to navigate this evolving situation, we believe providing additional context for the impact COVID-19 is having on our business is appropriate and helpful to our stakeholders. We believe the impact to our business is temporary and would like to proactively share information on our situation. Our bookings performance to date is ahead of forecast which is consistent with the robust spending typically seen in the first quarter as our customers prepare for annual maintenance outages that take place in the spring. We have observed some softening in order volumes in Europe and a more pronounced decline in China, as expected, as a result of the coronavirus. That said, most of our customers are operating and many of our packaging and tissue customers are seeing a surge in demand for their products. To date, no Kadant employees have tested positive for COVID-19, and currently all 20 of our manufacturing locations around the globe are fully operational, including our three plants in China. Our strong footing in China gave us early insights into the outbreak allowing us to better prepare action plans at our manufacturing facilities located in other regions."

17:04 EDT Forum Energy withdraws Q1, FY20 guidance - CEO Cris Gaut says: "We are closely monitoring the impact of COVID-19 to ensure the safety of our employees, while we preserve business continuity and work to meet our customers' needs. Given the collapse in oil prices and the rapidly devolving outlook for drilling and completions spending, our guidance for the company's financial performance for Q1 and FY20 previously provided during our fourth quarter earnings call is withdrawn and investors should no longer rely on this guidance. We expect our results of operations, including operating cash flow, for the first quarter and the full year 2020 to be negatively impacted as a result of lower demand for our products and by supply chain disruptions. This statement replaces and supersedes any previously issued guidance or forecast. Forum is a capital light and scalable business. In response to the change in outlook, we will be undertaking a number of cost reduction actions in an effort to further align the business with market activity levels. We will also continue to emphasize our winning products, many of which are aimed at cost and operating efficiency for our customers, which are critical in a low oil price environment. Forum has been in discussions with the largest holder of its 6.25% Senior Unsecured Notes due October, 2021, regarding a potential exchange of the Notes. In light of recent market developments, the company and such noteholder have been unable to come to a mutual agreement for the transaction at this time. The company will continue to evaluate liability management alternatives for the Notes prior to their October 2021 maturity."

17:02 EDT Noodles & Company offers free delivery through March 31 - Noodles & Company announced it now offers free delivery through Noodles.com, effective through March 31 at participating locations. In addition to delivery through Noodles.com, Noodles is offering free delivery nationwide via DoorDash and Uber Eats.

16:53 EDT Ducommun Chairman Stephen Oswald buys almost $317K in company shares - Ducommun Chairman Stephen Oswald disclosed in a filing that he had purchased 15,000 shares of company stock at an average price of $21.10 per share on March 17. The total transaction value of the purchase was $316,500.

16:47 EDT Tesla to suspend production in Fremont, CA and NY facilities - The company states: "In the past few days, we have met with local, state and federal officials. We have followed and are continuing to follow all legal directions and safety guidelines with respect to the operations of our facilities, and have honored the Federal Government's direction to continue operating. Despite taking all known health precautions, continued operations in certain locations has caused challenges for our employees, their families and our suppliers. As such, we have decided to temporarily suspend production at our factory in Fremont, from end of day March 23, which will allow an orderly shutdown. Basic operations will continue in order to support our vehicle and energy service operations and charging infrastructure, as directed by the local, state and federal authorities. Our factory in New York will temporarily suspend production as well, except for those parts and supplies necessary for service, infrastructure and critical supply chains. Operations of our others facilities will continue, including Nevada and our service and Supercharging network. In many locations, we are in the process of implementing "touchless deliveries" so customers can continue to take delivery of their vehicle in a seamless and safe way. Due to the unique over-the-air connectivity of our vehicles, customers are able to unlock their new cars at a delivery parking lot via the Tesla App, sign any remaining relevant paperwork that has been placed in their car, and return that paperwork to an on-site drop-off location prior to leaving. Our cash position at the end of Q4 2019 was $6.3B before our recent $2.3B capital raise. We believe this level of liquidity is sufficient to successfully navigate an extended period of uncertainty. At the end of Q4 2019, we had available credit lines worth approximately $3B including working capital lines for all regions as well as financing for the expansion of our Shanghai factory."

16:41 EDT StoneMor Partners to sell all California assets for $49.2M - StoneMor announced it has signed a definitive agreement to sell the assets of Olivet Memorial Park, Olivet Funeral and Cremation Services and Olivet Memorial Park and Crematory located in Colma, California, to Cypress Lawn Cemetery Association for a total purchase price of $42.1M - $25M in cash plus $17.1M in assumption of lot takedown obligations, subject to certain adjustments and credits. Additionally, StoneMor announced that it has a signed separate definitive agreement to sell the assets of its remaining California locations to entities owned by John Yeatman and Guy Saxton for a total purchase price of $7.1 million in cash, subject to certain closing adjustments. The transactions, which are expected to result in a gain, are targeted to close, subject to confirmatory due diligence and regulatory approvals, in the next 60 days.

16:38 EDT Altria Group temporarily suspends operations at Richmond Manufacturing Center - Altria Group announced that it is temporarily suspending operations at PM USA's Manufacturing Center in Richmond, Virginia, out of an abundance of caution after learning last night that a second PM USA employee tested positive for COVID-19. The company expects the Manufacturing Center to suspend operations for the next two weeks, though PM USA will continue to monitor the evolving situation. PM USA has actively implemented business continuity plans and believes it has sufficient finished goods cigarette inventory for approximately two months based on current estimated shipping volume, in addition to current wholesale and retail inventories. Separately, some Middleton domestic operations will also be suspended for two weeks due to COVID-19 related supply chain constraints. Middleton believes it has sufficient finished goods cigar inventory for approximately three months based on current estimated shipping volume, in addition to current wholesale and retail inventories. "We are committed to protecting the safety and well-being of our employees, contractors, their families and the communities where we operate," said Billy Gifford, Altria's Vice Chairman and CFO. "We take the threat of COVID-19 seriously and have been actively implementing plans to minimize business disruptions and their potential impact to our employees, consumers and customers." During this temporary two-week suspension of plant operations, PM USA and Middleton will pay employees their regular base wages. PM USA and Middleton will evaluate providing additional pay continuation beyond that timeframe as needed. Altria continues to follow updates from public health authorities and implementing CDC-recommended precautions including travel restrictions, remote working, and social distancing.

16:36 EDT International Money Express temporarily closes U.S. stores amid COVID-19 spread - International Money Express provided a business update regarding the ongoing impact of COVID-19. "At International Money Express, the well-being of our customers and employees is at the center of everything we do. In response to the COVID-19 crisis, all of our United States based headquarters personnel have been empowered to work from home to protect themselves and their families," the company said. "We have also temporarily closed our 33 company-owned stores around the country to further help mitigate the spread of the virus. Aside from these limited store closures, our money transfer services continue to operate at full capacity and serve our communities across the US and Canada. In fact, we have seen our in-store business increase across the country since the crisis began. We have also experienced great growth through our online platform at www.intermexonline.com where both new and existing customers enjoy comparable service levels to our in-store experience. Month to date through the first two weeks of March, we have seen year over year growth in our online business of 219%. Similarly, we have grown our online volumes by over 42% from the month of February, 2020. International Money Express remains very well capitalized during this crisis, and is grateful to be able to continue to provide the remittance services which are so critical to our customers."

16:34 EDT Flexible Solutions suspends dividend until further notice - Flexible Solutions announces that due to current circumstances related to the COVID-19 crisis the board of directors has decided to suspend the regular dividend until further notice, stating: "The length and intensity of the disruptions to the world economy as a result of the Covid-19 crisis are not known at this time. The risks to FSI's business are equally unpredictable. Therefore, conserving capital is the proper response to risks which will only become quantifiable several months in the future."

16:32 EDT Hersha Hospitality announces liquidity enhancing measures - The company said, "Hersha Hospitality Trust has taken measures to enhance the liquidity profile of the Company and its properties during this unprecedented operating environment. These initiatives include: Comprehensive containment of operating expenses through deep cost cuts, restructuring, and select closing of hotels. Reducing floor operations and closing restaurants and bars to "shrink" hotels to more efficiently serve our limited guest count and curb expenses. Suspending planned capital expenditures for the balance of the year, resulting in $10 million to $15 million of estimated savings. CEO & COO reducing salary by 50% and the Board of Trustees electing to take all payments in stock for the remainder of 2020, resulting in cash preservation and additional liquidity. The Company's top priority during this uncertain time is maintaining adequate liquidity as we manage the Company under the press and uncertainty of the COVID-19 virus and its effect on the travel and hospitality industries. In addition to the previously announced asset dispositions, the Company continues to explore various asset sales and is in active dialogue with our lending partners and bank group to shore up capital available on our $250 million unsecured credit facility. Furthermore, as a part of the Company's plan to preserve cash, the Company is revoking the previously declared dividends from March 5, 2020 on its common shares, 6.875% Series C Cumulative Redeemable Preferred Shares, 6.50% Series D Cumulative Redeemable Preferred Shares and 6.50% Series E Cumulative Redeemable Preferred Shares. Our Board of Trustees will continue to review the Company's performance on a quarterly basis until an appropriate time for reinstatement is determined. We anticipate suspending our common and preferred dividend distributions for the balance of the year, generating additional cash liquidity of approximately $72.5 million for 2020 based on last year's distribution rates. While we are adapting our operations and implementing cost reduction strategies in response to the national crisis, the Company is prioritizing liquidity above all until the operating environment becomes more clear. The Company will continue to review taxable income on a regular basis and take measures, if necessary, to ensure that it continues to meet the minimum distribution requirements to maintain its status as a real estate investment trust. Unpaid dividends on Hersha's preferred shares shall accrue without interest. No cash dividends may be paid on Hersha's common shares unless all accrued but unpaid dividends on its preferred shares have been (or contemporaneously are) declared and paid, or declared and a sum sufficient for such payment has been set apart for payment for all past dividend periods.Our executive team has navigated three cycles together, including previously unprecedented demand shocks such as September 11, 2001 and the Great Financial Crisis. We expect a very difficult environment throughout 2020 and particularly across the second and third quarters, but we have faith in our healthcare system to expeditiously support the country through this trying time. Our purpose-built portfolio, reconstructed and holistically renovated across the last five years, resides in some of the most valuable urban, gateway markets in the US and is positioned to welcome back all of our loyal and first-time guests when fears abate and the world's population can resume their love of travel. As active revenue and asset managers we are confident that the strategies we have implemented to reduce expenses and enhance our liquidity will allow us to weather this storm and ultimately lead to value creation as the country recovers from this extraordinary event."

16:31 EDT Dine Brands draws down $223M in revolving credit facility, pulls FY20 guidance - Dine Brands announced it has drawn down a total of approximately $223 million of the $225 million available under its revolving financing facility pursuant to its 2019-1 Variable Funding Senior Notes issued as part of the company's securitization refinancing in 2019. Although Dine Brands does not have an immediate need for additional liquidity, precautionary steps were taken to increase the company's financial flexibility in light of unprecedented conditions due to the COVID-19 outbreak. The proceeds will be used for general corporate purposes. The company believes its consolidated financial results for 2020 could be materially impacted by the growing global impact from COVID-19. As a result, the company has withdrawn its 2020 financial performance guidance issued on February 24, 2020.

16:18 EDT Americold Realty Trust reports continued operation through COVID-19 - Americold Realty Trust provided an update on the company's actions amid the COVID-19 pandemic. CEO Fred Boehler said, "Each day, frozen and refrigerated food destined for grocery stores, restaurants and other outlets flows through our global infrastructure. (....) We are working closely with our customers - leading food producers, retailers and distributors - to move products through the global food supply chain. In particular, we are working to support our many retail customers as they experience unprecedented demand for their products. Our network of over 180 integrated facilities remain operational and open for business, keeping retailers stocked."

16:18 EDT Fluor receives NYSE notice over Form 10-K filing - Fluor Corporation announced that it received a notice from the New York Stock Exchange indicating that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2019 with the Securities and Exchange Commission. The notice has no immediate effect on the listing of the company's stock on the NYSE. The NYSE informed the company that, under NYSE rules, the company will have six months from March 18, 2020 to file the 2019 Form 10-K with the SEC. The company can regain compliance with the NYSE listing standards at any time prior to that date by filing its 2019 Form 10-K. If the company fails to file the 2019 Form 10-K before the NYSE's compliance deadline, the NYSE may grant, at its sole discretion, an extension of up to six additional months for the company to regain compliance, depending on the specific circumstances. The notice from the NYSE also notes that the NYSE may nevertheless commence delisting proceedings at any time if it deems that the circumstances warrant.

16:14 EDT Physicians Realty Trust withdraws 2020 acquisition guidance - Physicians Realty Trust has provided a Supplemental Update pertaining to the ongoing COVID-19 pandemic. The company's observations are based on current information and may change as the pandemic evolves. John T. Thomas, President and Chief Executive Officer of the Company, commented, "While we are proud to declare and pay our 27th consecutive quarterly dividend, our thoughts, hearts, and prayers are with all of our DOC team and families, and the healthcare providers that we are proud to call our partners during this period of national crisis. Just as we have faith in our nation's healthcare providers as they respond to the ongoing COVID-19 pandemic, we believe in the resiliency of DOC's medical office portfolio in the presence of unprecedented demand on our healthcare system and market volatility. Our portfolio was built with an emphasis on assets critical to the delivery of essential outpatient care occupied by the world's largest investment grade and credit worthy health systems. We funded these investments through the conservative use of equity and to a lesser extent long term leverage: a formula that we believe places us at an advantage during this time of uncertainty. Our average remaining lease term is over 7 years and our balance sheet is strong, as noted in the Supplemental Update provided on our website. We anticipated higher acquisition growth in 2020, but in light of current capital market conditions, we are withdrawing our 2020 acquisition guidance for now. We will monitor the needs of our current client and investment opportunities, consistent with our history of prudent allocations of capital."

16:09 EDT Centennial reduces operated rig program to one rig from five rigs - As a result of the recent decline in crude oil prices and ongoing uncertainty regarding the oil supply-demand macro environment, Centennial Resource Development announced that it has reduced its operated rig program from five rigs at the beginning of the month to one currently. As a result, the company anticipates that its capital expenditure budget for 2020 will be approximately 50% lower than the annual guidance ranges provided in late February, assuming the company continues to run one rig for the remainder of the year. Centennial will continue to monitor changes in commodity prices and may further adjust its capital program for the remainder of the year in response to such changes. The company expects to update its detailed 2020 financial and operational plan concurrent with the release of its Q1 financial results; therefore, the guidance issued on February 24 should no longer be relied upon. Additionally, the company has entered into fixed price oil swaps for April through September of 2020 to protect against possible, additional near-term declines in oil prices. During this period, the company has hedged approximately 25,500 barrels per day of oil at a weighted average price of $26.08 per barrel.

16:07 EDT Acadia says balance sheet remains strong, suspends sale process of UK unit - CEO Debbie Osteen says: "Today, we face an unprecedented global event with the COVID-19 pandemic. Though we do not know exactly how this situation will unfold, we are carefully monitoring the impact to our business and believe Acadia is well-positioned to support our patient population and continue to grow our business. We believe the demand for mental health and substance use treatment is not discretionary or elective. We continue to see demand across our services lines consistent with our expectations. As we disclosed when we announced financial results on February 27, 2020, we commenced a formal process regarding the sale of our U.K. business in January and received multiple indications of interest. While the interest from potential buyers remains strong, given evolving market dynamics related to the COVID-19 pandemic, we have decided to temporarily suspend the sale process until market conditions improve. Our objective continues to be maximizing value for our stockholders. At this time, our focus is on serving our patients in the U.K. to the very best of our ability and ensuring the safety and health of our employees. Our balance sheet remains strong, and we have adequate liquidity and capital to invest in and grow our business. Acadia had $90 million in cash and cash equivalents and full availability under its $500 million revolving credit facility as of February 29, 2020. As we emerge from this difficult time, we believe our services will be in greater need, and we will be very well-positioned to meet that demand."

16:07 EDT J&J says supply chain 'currently holding steady and meeting patient needs' - Johnson & Johnson's Chief Global Supply Chain Officer, Kathy Wengel, shared the measures the company has taken to maintain its supply chain operations during the current novel coronavirus outbreak in a post to the company's site. Wengel stated in part: "As the world rapidly learns to adapt to an ever-changing landscape, Johnson & Johnson's supply chain, which produces everything from contact lenses to prescription medications to baby shampoo, is currently holding steady and meeting patient needs. Thanks to dedicated employees around the globe and robust business continuity plans, Johnson & Johnson is able to deliver for the one billion customers and patients who rely on its products during this unprecedented time." Reference Link

16:04 EDT Lexicon to close out two sotagliflozin trials early due to COVID-19 uncertainty - Lexicon provided an update on its Zynquista program in type 2 diabetes, heart failure and chronic kidney disease. The company will close out early the two long-term outcomes studies of sotagliflozin, SCORED and SOLOIST, designed to demonstrate benefits in and support labeling for heart failure and chronic kidney disease. The decision to close out the studies early is based principally on the company's assessment that a near-term partnership sufficient to fund the studies to completion is now unlikely, together with uncertainties relating to the effects of the COVID-19 pandemic on the trials. Lexicon will work closely with investigators to proceed in a manner that is aligned with the best interests of patients still being treated on these studies.

16:02 EDT Masimo to acquire TNI medical AG; terms not stated - Masimo announced it has entered into a definitive agreement to acquire TNI medical AG, an innovative ventilation company headquartered in Wurzburg, Germany. In August 2019, Masimo disclosed an investment in TNI that included an exclusive option to acquire the company. TNI's softFlow technology is designed to provide high flow, warmed and humidified respiratory gases to spontaneously breathing patients suffering from serious pulmonary conditions. The softFlow technology provides efficient, quiet and comfortable respiratory support by generating a precisely regulated, stable high flow of room air or a mix of room air and oxygen. The system, comprised of an integrated flow generator, respiratory circuit, and patient interface, operates without the need of pneumatic systems (i.e. compressed air supplied from the hospital wall) and can be used both in the hospital and at home. The transaction is expected to close in the second quarter of 2020, subject to customary closing conditions. Masimo expects to fund the acquisition with existing cash on hand and expects the transaction to have an immaterial impact to net earnings in 2020.

15:48 EDT State Department advises U.S. citizens to avoid all international travel - The Department of State advises U.S. citizens to avoid all international travel due to the global impact of COVID-19. In countries where commercial departure options remain available, U.S. citizens who live in the United States should arrange for immediate return to the United States, unless they are prepared to remain abroad for an indefinite period. U.S. citizens who live abroad should avoid all international travel. Many countries are experiencing COVID-19 outbreaks and implementing travel restrictions and mandatory quarantines, closing borders, and prohibiting non-citizens from entry with little advance notice. Airlines have cancelled many international flights and several cruise operators have suspended operations or cancelled trips. If you choose to travel internationally, your travel plans may be severely disrupted, and you may be forced to remain outside of the United States for an indefinite timeframe. Publicly traded companies that may be impacted by this include: Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Airlines (UAL). Reference Link

15:32 EDT Canon Medical to develop rapid genetic testing system for COVID-19 - Canon U.S.A. said that Canon Medical System announced the start of development of a rapid genetic testing system for the novel coronavirus, reaffirming Canon Medical's commitment to the basic research and development of rapid diagnostic test kits. This project is part of a research program focusing on the development of diagnostic methods for COVID-19 led by the Japan Agency for Medical Research. Canon Medical was selected to participate in this research program in cooperation with Nagasaki University. This was in recognition of Canon Medical's strength in leveraging its technologies in delivering practical solutions to support medical emergencies, notably by supplying Ebola rapid test kits to the Republic of Guinea in 20152, donating Ebola rapid test kits to the Democratic Republic of the Congo in 2019, and through the manufacturing approval and sale of the Genelyzer KIT in 20183. The test and the reagents being developed for COVID-19 RNA testing is based on the LAMP method developed by Eiken Chemical Co., Ltd., and are to be used with a compact isothermal amplified gene fluorescent detector manufactured by Canon Medical to detect the presence of virus. Compared to the conventional test method of real-time PCR, the LAMP method allows for detection of the virus to be performed more easily and quickly, which makes it suitable for testing in local areas where infection is prevalent.

15:25 EDT CB Financial Services suspends stock repurchase program - CB Financial Services announced that it has joined other banking institutions in suspending its stock repurchase program. The program has been suspended until further notice. To date, the company has repurchased 69,966 shares totaling $2.0M of the $5.0M authorized for repurchase under the program.

15:17 EDT CVS opens COVID-19 testing site in Shrewsbury, Massachusetts - CVS said that, in close coordination with the U.S. Department of Health and Human Services, the U.S. Public Health Service, and Governor Charlie Baker's administration, it is opening a COVID-19 testing site for a limited population in the parking lot of a CVS Pharmacy in Shrewsbury, Massachusetts. "It's important to understand that this is our first site, which means there will likely be issues that arise," the company said. "Those issues will be addressed immediately and inform the opening of other sites - in CVS Pharmacy parking lots and elsewhere. The goal is to serve as a model for testing." Testing will initially focus on a critical population: first responders and health care workers. State officials have identified a group of brave women and men who are on the frontlines of the pandemic and have potentially been exposed to COVID-19. The sooner they are tested, the sooner they can continue to help others, in particular the most vulnerable members of our communities.

15:02 EDT LabCorp sets dedicated hours for non-COVID-19 testing for 'most vulnerable' - LabCorp announced that it is dedicating the first hour of service each day at its nearly 2,000 patient service centers across the U.S. for the non-COVID-19 testing needs of its most vulnerable patients. "LabCorp's first business hour of each day at PSCs will be focused on serving people who are 65 or older or who have serious underlying health conditions. LabCorp will not turn away any patient during the first business hour but encourages other patients to plan around this hour to protect vulnerable patients. Patients who believe they have been exposed to COVID-19 should not enter the patient service center. They should contact their physician or healthcare provider," the company said.

14:57 EDT Pembina Pipeline announces receipt of FERC approval for Jordan Cove project - Pembina Pipeline announces receipt of a certificate of approval from the U.S. Federal Energy Regulatory Commission, or FERC, for Pembina's proposed Jordan Cove liquified natural gas terminal and Pacific Connector Gas Pipeline. "Jordan Cove is the first ever U.S. West Coast natural gas export facility to be approved by FERC. This federal approval is a significant milestone for the Project and for Pembina," the company said.

14:50 EDT TJX CEO says entered 2020 in 'very strong' position, taking 'prudent steps' - TJX Companies issued the following statement from TJX CEO and President Ernie Herrman following the company's COVID-19 update press release on Thursday, March 19: "TJX is a great company with a great retail model. I want to reiterate that TJX entered 2020 in a very strong financial position. We consider the actions that we announced today as just prudent steps we are taking to further strengthen our financial liquidity and flexibility during this uncertain environment. Additionally, while we are evaluating our dividend in the near term, I want to emphasize that we remain committed to paying our dividends whenever the environment normalizes for the long term, as we have been for decades. With a 43-year history as a company, our management team and amazing organization are focused on managing through these unprecedented times for the long-term success of our company."

14:39 EDT Organovo founder to vote against proposed merger with Tarveda - Keith Murphy, founder and former CEO of Organovo Holdings, issued a letter to stockholders in connection with the company's prospective merger with Tarveda Therapeutics, in which he states in part: "The Board of Directors of Organovo Holdings is in the process of asking stockholders to support its proposal to merge with Tarveda Therapeutics, a company with uninspiring science and few other financial options. However, there have been a number of decisions and actions from the Board that suggest that its judgment and recommendations should not be trusted at all. After my departure in 2017, the decisions made by the Board call into question why anyone would vote for a plan that it proposes. Time and again, the current mix of directors have demonstrated that the best course for stockholders is to avoid trusting the Board...Organovo's Board is asking stockholders to support its proposal to merge with Tarveda, a company with uninspiring science and few other financial options. However, a simple review of this Board's performance and decisions after mid-2017 reveals a track record that suggests the Board's business judgment and recommendations should not be trusted at all. Rather than blindly supporting the Board's recommendations, I am voting AGAINST the Tarveda merger, and will continue to push the Board to engage with active stockholders on an option that will lead to a better outcome."

14:36 EDT Movie theater stocks spike higher after bailout request - Shares of movie theater operators are rallying after an industry group, the National Association of Theater Owners, or NATO, lobbied Congress to consider relief efforts after the coronavirus fallout. CORONAVIRUS CLOSING: Movie theater chains across the U.S have been forced to close their doors to prevent the spread of coronavirus. BAILOUT PLEASE: The trade group that representing movie theaters in the U.S., the National Association of Theater Owners, has asked for immediate help on Thursday morning. The organization, which represents most of the industry's cinemas, said that it's asking for immediate federal help for its chains and its 150,000 employees. The theaters are requesting loan guarantees for exhibitors, tax benefits for employees and funds to compensate for lost ticket sales and concessions. NATO warned that the movie theater industry is "uniquely vulnerable" to the crisis, and needs assistance to weather a near-total shutdown of two to three months. "This is an unprecedented challenge to the business," said John Fithian, CEO of NATO. "We're looking to Congress and White House to understand this is a cultural institution where people gather." Fithian didn't give a specific dollar amount for what the industry is seeking, but said theaters could be saved for a fraction of what the airline industry is requesting -- The White House has proposed $50B for the airlines. For less than the cost of one airline company, Fithian said, movie theaters could be kept afloat. "We want our policymakers to know that at the end of this thing, when people have been cooped up in their house for several months, they'll need a break to go out and do something collectively that's affordable and fun and away from what they've just been through," he said. "But we still need to be viable." PRICE ACTION: Shares of companies in the movie theater space are trading higher, including AMC Entertainment (AMC), Marcus (MCS), Cineworld Group (CNNWF), Imax (IMAX), and Cinemark Holdings (CNK).

14:29 EDT Gilead says supporting five clinical trials of remdesivir for COVID-19 - CNBC's Meg Tirrell provided a statement from Gilead on Twitter about the status of remdesivir as a treatment for the novel coronavirus: "Gilead is working with urgency to respond to the pressing need for an effective treatment for COVID-19. Remdesivir is an investigational antiviral with limited data at this time -- it is not approved anywhere globally and has not been demonstrated to be safe for effective for any use. Gilead is supporting five clinical trials of remdesivir around the world -- three of which are enrolling patients in the United States -- to rapidly determine the safety and efficacy of remdesivir as a potential treatment for COVID-19. In addition, a large number of severely ill patients have received remdesivir for COVID-19 through the compassionate use program. We are in discussions with regulatory agencies, including FDA, to determine the most appropriate pathway for approval of remdesivir in the even that the data are not positive. We will continue to work with urgency and partner with regulatory authorities, hospitals and healthcare providers around the world as we work together to deliver effective interventions for this global health emergency." Reference Link

14:14 EDT eBay calls Starboard's actions 'unwarranted, unreasonable, detrimental' - eBay issued the following statement in response to the letter from Starboard Value LP announcing that it has nominated four candidates to stand for election to the company's board at eBay's 2020 Annual Meeting of Stockholders. "After extensive private discussions and engagement with Starboard's representatives, eBay's board believes Starboard's nominations are unwarranted and unreasonable, particularly in light of the decisive actions eBay has taken, and is taking, including a CEO search process that includes external and internal candidates. eBay's efforts have been positively received by our investors and market analysts. Starboard's 'campaign platform' is constantly changing and does not include useful suggestions or meaningful content. The board currently includes a principal of a major activist investor (Elliott Management) and a director jointly nominated and agreed upon with Starboard one year ago. These new directors have been integrated into the board and their perspectives and contributions are valued. It is unclear what Starboard is hoping to accomplish through the appointment of four more candidates, other than to create unnecessary distraction and, as a relatively small minority investor, to obtain an outsized role on the board. Moreover, we are disappointed that Starboard has decided to announce its previously provided nominations amidst the global COVID-19 pandemic while the board and management are trying to focus on the business, employee health and safety, and the important CEO search and portfolio review that are underway. eBay has maintained a frequent and substantive dialogue with Starboard over the last 18 months. eBay's efforts have been a genuine attempt to engage constructively; in our view, Starboard's have not."

14:02 EDT Taubman to temporarily close shopping centers in response to COVID-19 - Taubman Centers announced the temporary closures of all but two of the company's U.S. shopping centers in response to COVID-19. The closures will be effective at the close of business on March 19 and will continue through March 29, or later if required by state or local government. In some markets, restaurants or other tenants with exterior public entrances at enclosed malls may stay open at their discretion, as and to the extent permitted by law. Businesses with entrances inside of the mall will be closed. Tenants at the company's open-air, street-front retail centers - Country Club Plaza in Kansas City, Mo. and International Market Place in Waikiki, Hawaii - may continue to operate. "After numerous discussions with state and local officials, we will temporarily cease operations in all but two centers this evening," said the company's Chairman, President and CEO Robert Taubman. "We are clearly in unprecedented times and this is right decision for our shoppers, retailers, employees and these communities."

13:51 EDT PNC Financial adjusting branch operating hours, practices - PNC Bank announced that it will implement temporary retail branch adjustments. "PNC is taking these steps to help stop the spread of the coronavirus, while minimizing disruption of the service it provides to customers," the bank said. The changes, which will go into effect Friday, March 20, will include operating primarily in a drive-up only mode, augmented with select branches that do not provide drive-up capability, to ensure branch access across PNC communities. Together, about three quarters of PNC's current branch locations will remain open to service customers. The remainder of PNC branches will be closed until further notice. The company said branch hours for all open locations will be 10:00 a.m. to 5:00 p.m. Monday through Friday and 9:00 a.m. to 1:00 p.m. Saturday, closed on Sunday. The bank is offering essential appointments for customers requiring safe deposit box access, loan closings or other banking services that cannot be delivered through the drive-up, by telephone, through the ATM network or via mobile or online banking.

13:10 EDT Carnival offers governments to consider cruise ships as temporary hospitals - Carnival Corporation & plc announced that select cruise ships from the company's global cruise line brands, including Carnival Cruise Line, Holland America Line, Princess Cruises and P&O Cruises Australia, will be made available to communities for use as temporary hospitals to help address the escalating impacts of the COVID-19 pandemic on healthcare systems around the world. "With the continued spread of COVID-19 expected to exert added pressure on land-based healthcare facilities, including a possible shortage of hospital beds, Carnival Corporation and its brands are calling on governments and health authorities to consider using cruise ships as temporary healthcare facilities to treat non-COVID-19 patients, freeing up additional space and expanding capacity in land-based hospitals to treat cases of COVID-19. As part of the offer, interested parties will be asked to cover only the essential costs of the ship's operations while in port...The temporary hospital cruise ships would be berthed at a pier near the community in need and operated by the ship's crew, with all maritime operations, food and beverage, and cleaning services provided by crew members on the ship. Medical services would be provided by the government entity or hospital responsible for fighting the spread of COVID-19 within that community," the company said.

12:38 EDT Bayer in talks with White House, FDA on malaria treatment Resochin for COVID-19 - Bayer announced it is joining the U.S. Government's fight against COVID-19 with a donation of 3 million tablets of the drug Resochin, chloroquine phosphate. Resochin, a product discovered by Bayer in 1934 and indicated for prevention and treatment of malaria, also appears to have broad spectrum antiviral properties and effects on the body's immune response. New data from initial preclinical and evolving clinical research conducted in China, while limited, shows potential for the use of Resochin in treating patients with COVID-19 infection. Bayer in recent days has been in talks with the White House, HHS, CDC, and the FDA, offering any assistance we can provide with a focus on donating Resochin to help in the government's efforts to combat the virus. Currently not approved for use in the United States, Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug's use in the U.S. Bayer thanks the Trump administration for moving quickly to enable this donation and will continue to work closely with the administration to support its efforts in the fight against COVID-19.

12:32 EDT Ocean Bio-Chemical reports expansion of production capacity for performacide - Ocean Bio-Chem has announced that its subsidiary manufacturing plant, Kinpak Inc. in Montgomery, Alabama has increased its number of shifts and is actively hiring additional personnel to try and meet overwhelming demand for its disinfectant product Performacide. In addition, they have taken steps to expand overall production capacity with the purchase of additional equipment. Performacide is an EPA-registered disinfectant and sanitizer that is proven to kill previously known strands of human Coronavirus, and meets EPA criteria for use against the new, SARS-CoV-2, the cause of COVID-19. Performacide utilizes Chlorine Dioxide for disinfection, which is a gas dissolved in water, and offers unique advantages over many other traditional disinfectants. It requires no cleanup after use, lowering user error found in many commercial applications when uses as directed. Performacide kills viruses* and bacteria and then dissipates into the air leaving no carcinogens or poisonous residuals. A strong oxidizer, it also removes foul smells, including cigarette smoke, as well as allergens. Performacide ships as a small, easily stored dry pouch that the user drops into a container of water. This makes it ideal for use in both commercial and residential settings. OBCI said it believes that using Performacide will reduce chances of user error, decrease the amount of time spent disinfecting, and help prevent the spread of COVID-19.

12:15 EDT FDA's Hahn says working 'very closely' with Gilead on remdesivir - Asked about a potential timeline for approval of Gilead's remdesivir, FDA Commission Stephen Hahn said he is prohibited by law from discussing commercial timelines but added that the Agency and company are working "very closely" on the drug as a potential treatment for fighting COVID-19.

12:00 EDT W.P. Carey falls -23.0% - W.P. Carey is down -23.0%, or -$12.32 to $41.13.

12:00 EDT Britannia Bulk falls -40.0% - Britannia Bulk is down -40.0%, or -$11.21 to $16.80.

12:00 EDT USD Partners rises 130.8% - USD Partners is up 130.8%, or $2.21 to $3.90.

11:50 EDT Regeneron mentioned by Trump during update on coronavirus drug development - President Donald Trump, in an ongoing coronavirus update press conference from the White House, mentioned Regeneron among the companies working on treatments for COVID-19.

11:43 EDT TJX suspends share repurchase program, says evaluating dividend program

11:37 EDT Ericsson says all production sites are 'up and running' - Ericsson said that it is closely monitoring the development around the novel coronavirus and follows recommendations from relevant national authorities and international bodies, such as the World Health Organization. The responsibility for the health and safety of employees, customers and other stakeholders is the company's top priority. As of February 25, Ericsson restricted non-essential business travel globally. As of February 27, Ericsson implemented guidelines for private travel. Each employee is required to discuss their return to work with their manager before returning to the office. Employees who have visited countries that are considered high-risk have to work from home for 14 days after their return. As of March 11, Ericsson has decided to cancel and/or postpone all events for the coming three months until June 11, or until further notice. Ericsson plans to hold its Annual General Meeting (AGM) of shareholders 2020 as scheduled at 3:00 pm CEST on March 31, 2020, but will take precautionary measures to ensure the health and safety of shareholders, employees and other stakeholders. Due to the risk for spreading of the virus, Ericsson has decided to limit the scope of the meeting and the presence of Board members and management will be limited. Decisions about recommending or requiring employees to work remotely are made per site or country and is usually made in coordination with local authorities. Ericsson currently has a large number of employees working from home globally. As of today, all Ericsson's production sites are up and running. In line with recommendations from the Chinese authorities, Ericsson's production site in China was closed until February 9, but has been open since February 10.

11:35 EDT Lennar says balance sheet, asset impairments may be 'muted'

11:12 EDT Lennar chairman says has moved to 'appointment only' in sales centers

11:11 EDT Lennar chairman says has seen slowdown in traffic over last several days

11:11 EDT Lennar says Seattle employee died in March, had COVID-19

11:10 EDT Lennar CEO says still selling homes in current environment - Says new orders have continued to be "strong." Comments taken from Q1 earnings conference call.

10:31 EDT Maven acquires machine-learning personalization company LiftIgniter - Mavenannounced it signed and completed the acquisition of Petametrics, Inc., DBA LiftIgniter. This transaction marks the fourth technology platform closing for Maven in less than two years. "Our team's mission remains unchanged since the early days of digital media, which is to empower great journalism with great technology, material distribution, and monetization," said Maven founder James Heckman. "LiftIgniter enables and enhances all three of these focus areas. Its powerful personalization technology, together with Maven's leading edge technology stack, creates a product offering for publishers unmatched in the industry."

10:07 EDT Hoth Therapeutics: WEG232 treatment shows 71% reduction in SD-rats in trial - Hoth Therapeutics announced results from a preclinical study demonstrating the potential effectiveness of WEG232, a topical treatment with specific substance P-receptor inhibitor for Erlotinib-induced facial dermatitis and hair loss in cancer patients. The research, which took place at the George Washington University and supported by Hoth, suggests the topical application of WEG232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity. Robb Knie, CEO of Hoth, added, "This 12-week study with 25 SD-rats showed overwhelming compelling results of a 71% facial rash and hair loss reduction. Our next steps will be to further our preclinical work while also preparing for a pre-Investigational New Drug meeting request with the U.S. FDA. We look forward to publishing complete results of the aforementioned study in poster form prior to our pre-IND."

10:02 EDT Old National Bancorp to shift to appointment-only banking at all locations - Starting Friday, March 20, Old National will shift to appointment-only banking at all branch locations. This will enable members of the Old National staff to clean and disinfect surfaces after each visit. The drive-thru will remain open at all locations. Drive-thru hours of operation will not change. "As the coronavirus situation has evolved, we've learned that taking serious precautions now may be the best way to help our clients, colleagues and communities stay safe," said Old National Chairman & CEO Jim Ryan. "That's why we're making these important but temporary changes at our banking centers." Appointments will be available between 9 a.m. and 3 p.m. local time, with the first hour of each day reserved for those 60 or older and others who are deemed high-risk.

10:00 EDT Invesco Mortgage falls -25.0% - Invesco Mortgage is down -25.0%, or -$1.36 to $4.08.

10:00 EDT Direxion Daily Jr Gld Mnrs Bull 3X Shrs falls -28.0% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is down -28.0%, or -$1.42 to $3.66.

10:00 EDT BP Prudhoe Bay rises 16.2% - BP Prudhoe Bay is up 16.2%, or 55c to $3.94.

09:52 EDT XpresSpa seeks to support COVID-19 testing in 46 locations across 23 airports - XpresSpa Group announced that it has reached out to multiple government agencies, including the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services, as well as private laboratories across the country. The company said it has engaged in early high-level discussions with regards to turning all of its 46 airport locations, with many, located in point of entry cities, such as New York, Los Angeles, San Francisco, Chicago, Miami, Atlanta, and Washington DC into COVID-19 testing facilities. The company believes that its spas offer a range of spaces that can be set up to test airport staff, flight crews, and passengers. Doug Satzman, XpresSpa, Chief Executive Officer, said, "We believe we can we help alleviate some of the long waits for travelers entering the US but we can also be available to test TSA employees, pilots, Flight Attendants and other airport personnel who are on the front lines helping to keep our nation safe."

09:47 EDT Starwood Property falls -13.2% - Starwood Property is down -13.2%, or -$1.49 to $9.84.

09:47 EDT Guess rises 24.7% - Guess is up 24.7%, or 97c to $4.89.

09:47 EDT Blue Apron rises 57.5% - Blue Apron is up 57.5%, or $9.35 to $25.60.

09:35 EDT Disney says COVID-19 makes estimating future performance 'more challenging' - In a regulatory filing, Walt Disney Company stated: "The impact of the novel coronavirus, or COVID-19, and measures to prevent its spread are affecting our businesses in a number of ways. We have closed our theme parks; suspended our cruises and theatrical shows; delayed theatrical distribution of films both domestically and internationally; and experienced supply chain disruption and ad sales impacts. In addition there has been a disruption in creation and availability of content we rely on for our various distribution paths, including most significantly the cancellation of certain sports events and the shutting down of production of most film and television content. We expect the ultimate significance of the impact of these disruptions, including the extent of their adverse impact on our financial and operational results, will be dictated by the length of time that such disruptions continue which will, in turn, depend on the currently unknowable duration of the COVID-19 pandemic and the impact of governmental regulations that might be imposed in response to the pandemic. Our businesses could also be impacted should the disruptions from COVID-19 lead to changes in consumer behavior. The COVID-19 impact on the capital markets could impact our cost of borrowing. There are certain limitations on our ability to mitigate the adverse financial impact of these items, including the fixed costs of our theme park business. COVID-19 also makes it more challenging for management to estimate future performance of our businesses, particularly over the near to medium term."

09:30 EDT Wolverine World Wide withdraws guidance due to COVID-19 uncertainty - Due to the heightened uncertainty and recent volatility in the retail market relating to the potential impact of COVID-19 on the Company's operations, including its duration and effect on overall customer demand, the Company is withdrawing its guidance issued on February 25, 2020. The Company plans to provide more information during its first quarter earnings call.

09:23 EDT Telus commits $10M for COVID-19 response - In response to the COVID-19 pandemic, our TELUS Friendly Future Foundation has announced a $10M commitment to help urgently support and enhance public healthcare capacity and community response across Canada. This new funding will go toward purchasing new medical technology and equipment, such as ventilators, as well as increased support for food security, outreach to isolated seniors, virtual education programs, and mental health initiatives. The announcement builds on the considerable efforts currently underway by our TELUS team in respect of providing telemedicine and virtual healthcare solutions for Canadians, including home health monitoring and access to one-on-one video consultations with a licensed doctor at no cost on their smartphone and from the comfort and safety of their own home. These efforts will ensure that the full force of our 2020 impact is concentrated on one singular focus of increasing our collective ability to respond to the COVID-19 public health crisis. "During this unprecedented time of crisis, and reflecting our world-leading philanthropy and volunteerism in helping our fellow citizens, we are taking responsibility to ensure our communities are fully supported. Our $10 million commitment will enable swift funding solutions where they are needed most," said Darren Entwistle, President and CEO. "Whether providing frontline healthcare workers and vulnerable populations with supplies and technology that will keep them safe, or supporting those who are isolated and at risk during this time with virtual healthcare and mental wellness support, we will do whatever is required to help our citizens and save lives. The TELUS family is here for you: we will stand with our communities through the full duration of the COVID-19 crisis and well beyond, as we have always done. Please, be safe and stay connected, virtually, to your friends, family and those who need our support."

09:19 EDT Fortinet announces Fortinet Engage partner program - Fortinet recently introduced its new Fortinet Engage partner program. The program provides partners with specializations focused on growing markets, including SD-WAN and cloud, customized support and engagement flexibility to accelerate their business growth and expansion. Fortinet's Engage partner program addresses the required technology and sales skills needed from new network ecosystems, such as next-gen branch offices and dynamic cloud environments comprised of multi-cloud and hybrid cloud.

09:18 EDT SuperCom CEO to purchase up to 6 million shares - SuperCom CEO Arie Trabelsi has notified the company that he has increased his purchase program to purchase up to 6 million of the company's ordinary shares on the open market. Under the CEO purchase program, the CEO may purchase shares in open market transactions or through other authorized methods. This program does not require the purchase of any minimum number of shares.

09:17 EDT ECN says bank partner renews $600M funding commitment with Service Finance - ECN Capital announced that its operating subsidiary, Service Finance, has renewed its largest bank funding commitment. Over the next twelve months, this bank partner is committed to purchasing up to $600 million in Service Finance prime and super prime retail installment contracts for home improvement projects across all 50 states.

09:15 EDT IBM CEO says U.S. pension 'well over' 100% funded even after market selloff - IBM CEO Ginni Rometty is speaking on CNBC.

09:14 EDT IBM CEO says balance sheet 'very strong' - IBM CEO Ginni Rometty is speaking on CNBC.

09:13 EDT Worthington Specialty Processing announces consolidation of operations - Worthington Specialty Processing, a joint venture between Worthington Industries, Inc. (WOR) and United States Steel Corporation (X), announced a plan to consolidate its operations. Under the consolidation plan, WSP will close its Canton, Mich., facility. Its two remaining facilities in Jackson and Taylor, Mich. will continue to operate. The closure of the Canton operation is expected to be complete by May 29, 2020. WSP processes wide-sheet steel primarily for the auto industry. "Closing the Canton facility and consolidating operations is a move to bolster the ongoing competitiveness of WSP," said Jeff Klingler, president of Worthington's Steel Processing business. "We understand this can be a difficult time for employees and do not make these decisions lightly. Employees are encouraged to apply for open positions at Worthington facilities in the area. We will work with all employees to provide transitional services." WSP Canton has 91 employees. Approximately 66 positions will be impacted by the closure. The remaining positions provide centralized support services for WSP and will be moved to either Jackson or Taylor. WSP intends to sell the 195,000-square-foot processing center and the 250,000-square-foot distribution center located on Canton's 30-acre property, as well as most of Canton's fixed assets.

09:10 EDT Tennant promotes Dave Huml to COO - Tennant announced that Dave Huml, Tennant's senior VP, EMEA, APAC, global marketing and operations, has been promoted to COO, effective April 1. In this newly created role, Huml will continue to report to the company's president and CEO, Chris Killingstad, and will oversee all regional sales and service organizations, as well as global R&D, operations, IT and marketing. He also will help lead the execution of Tennant's new enterprise strategy by ensuring global alignment, prioritization and implementation. Huml brings more than 25 years of global leadership experience to the COO role. He joined Tennant in 2014 as senior VP in charge of global marketing.

09:10 EDT ToughBuilt continuing to employ entire workforce amid coronavirus - ToughBuilt Industries announced that despite recent conditions due to the coronavirus pandemic and resulting stock market turmoil, it is continuing to employ its entire workforce, while working remotely for their safety. The Company continues to supply products to its existing and new customers, both through traditional and online channels. CEO, Michael Panosian, said "I am especially proud of our dedicated "TOUGH TEAM" for their outstanding support and continued efforts to ensure a reliable supply chain and for bringing new products to market. This recent unfortunate turn of events highlights the importance of mutual cooperation with our retail partners and our online capability to continue shipping products for consumers across the globe. Fortunately, our factories are now back to almost full capacity, and we have sufficient inventory to meet demand. We will continue to monitor and adjust as needed to ensure supply, new product flow and continued growth strategies."

09:09 EDT Safe Bulkers adopts preferred stock repurchase program up to 100,000 shares - The Company announced that it has authorized a share repurchase program under which it may from time to time in the future purchase up to 100,000 shares of 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares, $0.01 par value per share, liquidation preference $25.00 per share and up to 100,000 shares of 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares, $0.01 par value per share, liquidation preference $25.00 per share. As of the date hereof, the Company has outstanding 2,300,000 shares of Series C Preferred Shares and 3,200,000 shares of Series D Preferred Shares.

09:07 EDT Generex provides guidance on safety of Ii-Key peptide vaccines - Generex Biotechnology provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the company's proprietary and patented Ii-Key immune system activation technology. This guidance is designed to assist third party groups and government agencies in their evaluation of potential vaccines against this pandemic SARS-CoV-2 virus. The patented NuGenerex Immuno-Oncology Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation. Generex is working with our partners at EpiVax who have identified such protein fragments or epitopes to generate Ii-Key-SARS 2 peptide vaccines in collaboration with our peptide manufacturing partners. The peptides and Ii-Key are made from naturally occurring amino acids, ensuring an excellent safety profile for Ii-Key peptide vaccines.

09:06 EDT Constellium to reduce or suspend activities at certain manufacturing sites - Constellium announced that it will reduce or suspend activities at certain of its manufacturing sites in recognition of the disruption caused by the COVID-19 virus to our people, customers and markets. Constellium's first priority is to protect its employees, their families and their communities. The company said, "We expect these actions to facilitate prompt and efficient resumption of full production levels once market conditions allow. In response to these developments and given the uncertainty regarding the duration and severity of the crisis, Constellium plans to aggressively reduce costs and capital expenditures, optimize working capital, and manage the supply chain to minimize the financial impact on the business. Constellium has already implemented proactive measures to protect the health and safety of its employees, in compliance with public health guidelines from the World Health Organization, and governmental and local regulations and recommendations. This includes increased cleaning and sanitization at its facilities, business travel ban, social distancing, strict policies for visitors and suppliers, and a work from home policy for employees at corporate offices. Constellium will continue to closely monitor the situation."

08:50 EDT Amplify Energy announces 37% reduction of 2020 capital expenditure budget - Amplify Energy announced that it has lowered its 2020 capital expenditure budget by approximately $17 million or 37% in response to the recent severe decline in commodity prices and overall downturn in the market attributed to COVID-19 and OPEC's decision to increase production. Full year capital expenditure guidance has been reduced from a midpoint estimate of $46 million to a midpoint estimate of $29 million. This revised capital budget is expected to be spent primarily in the first quarter of 2020, where Amplify is maintaining its prior guidance for capital spending of $13 to $19 million. Amplify also maintains a strong hedge book with 61% of forecasted 2020 production hedged, including 77% of crude oil hedged at $56.29 per barrel. As of March 18, 2020, Amplify's mark-to-market value was a net asset position of approximately $130 million. Due to Amplify's prudent hedging activities, the Company still expects to generate strong free cash flow for 2020 at current strip pricing. Additional detailed information on Amplify's hedge positions was posted on March 5, 2020 and is available on its website, www.amplifyenergy.com, under the Investor Relations section. Further, as a result of the oil price reduction, Amplify should qualify for statutory royalty relief at its Beta field following the end of the first quarter. This relief will reduce Amplify's royalty rate at Beta by 50%, resulting in an increase in production of approximately 500 Bbls/d and additional revenue of approximately $7 million per year at current prices. The company currently expects to receive this relief in the third quarter of 2020, subject to an application process which is expected to take approximately ninety days. It is important to note that despite current commodity prices, Amplify maintains over $170 million in liquidity and remains in full compliance with the financial covenants under its credit facility. Amplify is currently working collaboratively with the administrative agent on the upcoming Spring redetermination and will update the market at the appropriate time on our progress.

08:47 EDT BOQI International Medical completes acquisition of Chongqing Guanzan - BOQI International Medical announced that it has completed the acquisition of Chongqing Guanzan Technology. Chongqing Guanzan is a medical distributor with distribution channels covering over 4,000 pharmacies, over 4,000 clinics, 50 hospitals and 130 pharmaceutical companies nationwide. Chongqing Guanzan also has about ten world-leading medical device suppliers such as Stryker, GE, Siemens, Philips and Olympus. Recent important business updates of Chongqing Guanzan related to COVID-19 treatment include: On March 2, 2020, Chongqing Guanzan was authorized as the distributor of Jilin Morestep Medical's disposable protective coverall in Chongqing. On February 1, 2020, Chongqing Guanzan was authorized as the distributor of Nanjing Chenwei's medical ventilator and anesthesia machine in Chongqing. On January 1, 2020, Chongqing Guanzan was authorized as the distributor of Shenzhen Lanmage's digital radiography in Chongqing. As previously disclosed, on February 1, 2020, the Company entered into a stock purchase agreement with BEIJING XIN RONG XIN INDUSTRIAL DEVELOPMENT CO., LTD., a company organized under the laws of the People's Republic of China Chongqing Guanzan, a company organized under the laws of the PRC and Zhou Li, an individual residing in the PRC. Pursuant to the Agreement, Buyer, a wholly-owned subsidiary of the Company, will purchase all the issued and outstanding shares of Chongqing Guanzan from Seller. The aggregate purchase price for the Guanzan Shares is RMB 100,000,000, to be paid in 950,000 shares of common stock of the Company and RMB 80,000,000 in cash. The Stock Consideration was scheduled to be paid at closing and the Cash Consideration, which is subject to post-closing adjustments based on the performance of Chongqing Guanzan in 2020 and 2021, respectively, will be paid pursuant to a post-closing payment schedule. The transaction was closed on March 18, 2020. Upon Closing, the Guanzan Shares were transferred to and recorded under the name of Buyer and the Stock Consideration was paid to Seller through the issuance of 950,000 shares of the Company's common stock in accordance with the Agreement.

08:46 EDT Bright Horizons to close more than half of U.S.-based centers - In a regulatory 8-K filing released yesterday, Bright Horizons announced : "The recent outbreak of COVID-19 has disrupted Bright Horizons' operations in the United States, United Kingdom and the Netherlands. Bright Horizons' primary focus and attention is on the well-being and health and safety of the children and families we serve along with the teachers and staff at our centers. Our business is also critically important to supporting first responders, scientists and health care and medical professionals who are working tirelessly to respond to COVID-19. In response to the growing challenges presented by COVID-19 and in order to direct resources to best support our clients, families and staff, Bright Horizons will temporarily close more than half of its U.S.-based centers, while continuing to operate critical health care client and "hub" centers to provide care and support services to the children whose parents are working on the front lines of the nation's response, such as health care and medical professionals. At this time, neither the duration nor scope of the disruption can be predicted and, therefore, the negative financial impact to our results and future financial or operational performance, including our fiscal 2020 guidance, cannot be reasonably estimated. We will provide an update during our Q1 2020 earnings release and call. The situation is constantly changing, and we continue to work with our local teams on the operational and business impact."

08:44 EDT Chanticleer Holdings says merger scheduled to close on or about March 31 - Chanticleer Holdings announced the results of its special meeting of shareholders. On March 18, 2020, Chanticleer Holdings held a special meeting of shareholders at which all proposals voted on at the Special Meeting were approved by the shareholders of Chanticleer. Mike Pruitt, Chanticleer Holdings CEO stated, "We are pleased that our shareholders have approved all of the proposals included in our recent proxy statement. Importantly, shareholder approval now allows for both us and Sonnet BioTherapeutics, Inc. to move forward with the closing of our proposed merger transaction and the spin-off of Chanticleer's restaurant business. As we stated in our recent press release, the record date for the share distribution related to the spin-off of the restaurant business has been established as March 26, 2020. The spin-off and merger are expected to close on or around March 31, 2020, subject to satisfaction of certain closing conditions. All shareholders of record at the close of business on March 26, 2020 shall be eligible to receive shares of the spin-off on a pro-rata basis."

08:42 EDT CRA International appoints Daniel Mahoney as CFO - Charles River Associates (CRAI) announced the appointment of Daniel Mahoney as CFO effective March 30. Mahoney most recently served as Senior Vice President, Head of Finance at BrightSphere Investment Group (BSIG). Mr. Mahoney assumes the role from Chad Holmes, who will be CRA's Executive Vice President and Chief Corporate Development Officer, as part of a transition previously announced on February 27.

08:42 EDT Oramed receives positive feedback from EoP2 meeting with FDA - Oramed announced positive feedback from its initial End-of-Phase 2 meeting with the U.S. FDA to discuss Chemistry Manufacturing and Control of its lead oral insulin capsule ORMD-0801. The meeting, held in February, followed the successful completion of Oramed's Phase 2b trial of ORMD-0801 for the treatment of type 2 diabetes, which achieved its primary endpoint, the reduction in HbA1c compared to placebo at week 12. During this meeting the FDA provided feedback on key issues relating to Drug Product manufacture and supported continuing to Phase 3 clinical development. The company expects an additional meeting with the FDA following deeper analysis of the data from the Phase 2b trial, during which the company anticipates receiving the FDA's guidance on the Phase 3 study design. Oramed's CEO, Nadav Kidron, said, "We are very pleased with the productive and constructive feedback from the FDA as we continue on the path to bring oral insulin to market. We look forward to further discussions with the FDA and to their guidance in regards to our anticipated Phase 3 trial."

08:41 EDT T-Mobile financially prepared to close Sprint merger - T-Mobile announced that it is currently financially prepared to close its planned merger with Sprint, based on its previously secured commitments for bridge financing and senior credit facility financing, subject to the satisfaction of customary closing conditions under its commitment letter. The company has been in communication with all sixteen banks and has not received any notification that any of the banks are unprepared to fund their commitments to support the closing of the merger transaction. The companies continue to drive forward toward closing the merger as soon as possible. "I'm pleased that right now we have broad support from the banks to finance the closing of this merger - we are very close to unleashing the capabilities of the New T-Mobile, and that is even more important for consumers during the current COVID-19 pandemic," said John Legere, CEO of T-Mobile. "Our nation is more dependent than ever on connectivity, and we will continue to deliver our essential wireless service today and when we merge with Sprint, with a Nationwide 5G service that is broader and more robust than anything else in America. We can see the finish line and are prepared to close the merger very soon so our teams can get to work building a supercharged Un-carrier."

08:37 EDT Phathom Pharmaceuticals temporarily pauses patient randomization in trials - The company said. "Due to the COVID-19 global pandemic, the Company is temporarily pausing new patient randomization in its PHALCON-EE and PHALCON-HP clinical trials. The decision to temporarily pause new patient randomization was not based on any study-related COVID-19 infections or other safety events but rather an abundance of caution relating to the global efforts to combat the COVID-19 pandemic. The demands on medical institutions and clinicians during this unprecedented crisis were also an important consideration in this decision. The temporary pause on new patient randomization aligns with the American Society for Gastrointestinal Endoscopy's guidance on limiting endoscopies, which are required in both clinical trials, due to the COVID-19 pandemic and supports various governments' restrictions on travel. The Company has not experienced any interruption in its clinical trial supply at this time and is working closely with clinical trial sites in order to allow existing enrolled patients to continue in the PHALCON-EE and PHALCON-HP trials, while providing for their safety and the safety of physicians and other staff at the clinical trial sites. The Company will continue to monitor the situation and, as of this date, expects to remain on track to provide top-line data for both the PHALCON-EE and PHALCON-HP clinical trials in 2021."

08:36 EDT Phathom Pharmaceuticals expects data from PHALCON-EE in 2021 - Initiated PHALCON-EE, a pivotal Phase 3 clinical trial evaluating vonoprazan for both the healing and maintenance of healing of erosive esophagitis as well as the relief of heartburn. Top

08:28 EDT Cassava Sciences expects $5M cash use in FY20 - The company said, "Cassava Sciences expects to shortly announce full-year 2019 earnings and to file its Annual Report on Form 10-K. As of January 31, 2020, the Company had approximately $26 million of cash and no debt. Net cash use is expected to be approximately $5 million for full year 2020. Also, in March 2020, NIH awarded the Company supplemental research funding in the amount of $374,000. This new, non-dilutive research funding is intended to strengthen the Company's clinical program of PTI-125 in patients with Alzheimer's disease. In addition, the Company's trading window is now closed for employees and directors. A closed trading window prohibits insiders from trading in the securities of the Company prior to the announcement of clinical results of study Phase 2b and other unpublished material information. Finally, in the weeks ahead, management may conduct one or more non-deal roadshow. A NDRS is a multi-city series of meetings, virtual or in-person, with institutional investors to share public information and updates on the Company's business and vision for the future. Historically, Cassava Sciences has benefited from NDRSs by educating institutional investors about the Company, and by listening and learning from industry analysts, experts and investors."

08:26 EDT Cassava Sciences expects to run validation studies with SavaDx in 2H20 - The company said, "Cassava Sciences' diagnostic program, now called SavaDx, formerly known as PTI-125Dx, is focused on detecting Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. The goal of SavaDx is to make the detection of Alzheimer's disease as simple as getting a blood test. In September 2017, the Company announced a $1.8 million research grant award from NIH to fund the on-going development of SavaDx. The Company is still developing proprietary antibodies and other detection systems for use with SavaDx. Assuming technical success with on-going efforts, the Company expects to run validation studies with SavaDx in the second half of 2020. In addition, the Company expects to present a technical update for SavaDx at a major scientific conference in 2020."

08:23 EDT Cassava expects topline results from Phase 2b study of PTI-125 mid-year 2020 - The company said, "In September 2019, Cassava Sciences announced the initiation of a Phase 2b confirmatory clinical study in Alzheimer's patients, with funding provided by NIH. This Phase 2b clinical study is designed to evaluate safety, tolerability and drug effects of PTI-125 on biomarkers of disease. This blinded, randomized, placebo-controlled, multi-center, multi-dose research study has finished enrolling 64 patients with mild-to-moderate Alzheimer's disease. Study patients received either PTI-125 100 mg, 50 mg or matching placebo, twice-daily for 28 continuous days. The study was conducted in the U.S. across 9 clinical sites. The primary endpoint is improvements in levels of biomarkers of disease from baseline to Day 28. In January 2020, the Company announced the completion of patient enrollment for its Phase 2b study. In February 2020, the last study participants were successfully dosed. In March 2020, the last study participants underwent final, routine follow-ups. No safety issues were found. Cerebrospinal fluid and plasma samples from study participants were recently shipped to independent, third party labs for biomarker analysis. Study samples will be analyzed under blinded conditions, meaning no one will know whether a test sample came from a study participant who was on drug or placebo until the study is unblinded. Lab testing, statistical analysis, data analytics and interpretation of results are expected to run through approximately May 2020. The company expects to announce top-line results approximately mid-year 2020."

08:22 EDT NGL Energy Partners backs FY20 adjusted EBITDA view $565M-$595M - Specifically, the partnership has taken the following actions: High graded its FY21 planned capital expenditure budget to leverage off the significant infrastructure investment made during this past year and the current operating environment. As a result, management expects that for the fiscal year beginning April 1, growth capital expenditures will approximate $50M all of which would be funded using free cash flow. Reached an agreement to exit its gas blending business by March 31, with an expected reduction in working capital indebtedness of at least $50M and a further decrease in earnings volatility going forward.

08:21 EDT Cassava says focusing on development of first-in-class program for Alzheimer's - The company said, "Cassava Sciences is building a leading position in Alzheimer's R&D by focusing on the development of a first-in-class program for treating and detecting Alzheimer's disease. The Company's scientific approach for the treatment of Alzheimer's disease seeks to simultaneously improve both neurodegeneration and neuroinflammation. Cassava Sciences believes the ability to improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer's disease."

08:19 EDT Tracon Pharmaceuticals appoints Saundra Pelletier to board of directors - TRACON Pharmaceuticals (TCONO announced the appointment of Saundra Pelletier, CEO, President and Executive Director of Evofem Biosciences (EVFM), to its Board of Directors.

08:16 EDT Mateon Therapeutics partners with Meridian IT for drug manufacturing using AI - Mateon Therapeutics announced heir expanded focus on artificial intelligence enabled EdgePoint projects by expanding their partnership with Meridian IT. EdgePoint, the AI division of Mateon, was formed after the acquisition of PointR Data, Inc., that specializes in AI machine vision for the retail sector. In retail, the underlying Amazon Go-like technology enables automatic, cashier-less stores, which the EdgePoint team has implemented as a use-case in a convenience store chain with the help of Meridian. In this project, Meridian powers the underlying platform deploying these retail use cases leveraging AI Vision technologies. Mateon intends to leverage on the AI machine vision technology used in the retail use cases to pharmaceutical manufacturing, especially with our lead product OT-101, which we are testing for coronaviruses, including the current COVID-19. Under Mateon, this technology will be leveraged to bring drug manufacturing into the modern age. Because of regulatory concerns, much of drug manufacturing is stuck in legacy processes with operating procedures that are largely manual. These practices are inefficient and prone to errors burdened with extra personnel for control. The product is a novel application of AI neural networks and blockchain to ensure compliance with the FDA while ensuring ROI for manufacturers by slashing labor costs.

08:14 EDT Tehama County Air Pollution Control District deploys Envision Solar's EV charger - Envision Solar International announced that the Tehama County Air Pollution Control District in California has deployed the Company's EV ARC EV charging infrastructure product. The EV ARC makes free EV charging available to the public as part of the Carl Moyer Program in partnership with the California Air Resources Board. The station is now officially open to the public and is located in Red Bluff, CA, next to the Tehama County Agriculture Commission Department. The EV ARC was purchased through the mandatory California State contract issued to Envision in 2016 and renewed in 2018, using a grant by the Rural Assistance Program and the Air Control District.

08:12 EDT Avaya, Telarus sign master agent agreement - Avaya announced that Telarus has been named as a master agent for its Avaya Cloud Office by RingCentral offering. Avaya Cloud Office is a collaboration solution providing communications, file sharing, and collaboration capabilities across unified voice, video, messaging, digital customer engagement and meetings. Telarus will provide this new Avaya UCaaS offer to its extensive network of over 4,000 technology brokers.

08:11 EDT Singing Machine offers free access to Karaoke App catalog for 30 days - The Singing Machine Company announced it will be giving away free access to its Singing Machine Mobile Karaoke App's entire catalog of over 50,000 songs for 30 days. Gary Atkinson, Company CEO, commented, "At Singing Machine, we believe in the power of creating joy through music and bringing families together. With the global pandemic, our thoughts are with the people and families affected or self-quarantining at home. We recognize many schools around the country are closed and families are looking for ways to provide fun, engaging experiences within the home to bring families together." Singing Machine has partnered with Stingray to provide free access to its entire karaoke music catalog on the App. Singing Machine will also be offering 15% off its entire store and waiving shipping fees for a limited time.

08:10 EDT CHF Solutions says Aquadex Flow licensed, approved for sale in India - CHF Solutions announced the Aquadex FlexFlow system has been licensed and approved for sale in India, making ultrafiltration therapy available for patients suffering from hypervolemia, or fluid overload.

08:09 EDT Plenty of Fish launches innovative free livestreaming for dating - Dating app Plenty of Fish began rolling out a free livestreaming feature, dubbed LIVE!, for members to encourage singles to "date from a distance" as the nation practices social isolation. In partnership with The Meet Group, LIVE! enables Plenty of Fish app-users to livestream with friends and potential matches. U.S. Plenty of Fish app-users in the areas most impacted by Coronavirus, including New York, Washington and California, can begin livestreaming this week, as early as March 19. Next week, it is targeting to roll out to more than 80% of the U.S. and will be made available to all global app-users by the end of April. This feature comes at a time when singles around the world are asked to rapidly adapt to the new realities of social distancing and isolation, and are faced with exploring new ways to connect.

08:07 EDT NantKwest doses first patient in Phase 2 trial for second- and third-line MCC - NantKwest announced dosing of the first patient in a Phase 2 trial for second- and third-line Merkel cell carcinoma, or MCC, in patients who are refractory to immune checkpoint inhibitors. The trial will evaluate the company's first-in-class, off-the-shelf CD16-targeted natural killer, or haNK, cells in combination with ImmunityBio's IL-15 superagonist N-803 and Avelumab. The single-arm study will involve 43 patients who failed all standard of care treatments for MCC, including checkpoint therapy. Clinical trial sites are currently being activated.

08:05 EDT FGL Holdings announces expiration of "go-shop period" - FGL Holdings (FG) announced the expiration of the 40-day "go-shop period" provided for under the terms of the previously announced definitive merger agreement pursuant to which F&G will be acquired by Fidelity National Financial (FNF). F&G and its subsidiaries were permitted to actively solicit alternative acquisition proposals from third parties until 11:59 p.m. Eastern Time on March 18, the "go-shop period. During the go-shop period, F&G and its financial advisor, Credit Suisse, solicited 42 potential acquirers. Despite these efforts, F&G did not receive any alternative acquisition proposals during the go-shop period. Immediately following the expiration of the go-shop period, F&G became subject to customary "no-shop" restrictions on its ability to solicit alternative acquisition proposals from third parties and to provide non-public information to and engage in discussions or negotiations with third parties regarding alternative acquisition proposals, subject to certain customary exceptions. The transaction with FNF is expected to close in Q2 or Q3, subject to the satisfaction of customary closing conditions, including the receipt of regulatory clearances and approval by F&G shareholders.

08:05 EDT Arcadia Biosciences partners with Grow West, Buttonwillow Warehouse - Arcadia Biosciences announced a new strategic partnership with Grow West, one of the largest independent marketers of agricultural products in California, and Buttonwillow Warehouse Company, a family owned and operated fertilizer and crop protection products company in central and Southern California, to introduce Arcadia's USDA-compliant GoodHemp seed line to California growers. Under the terms of the agreement, Grow West and BWC will bring their collective grower relationships to Arcadia's GoodHemp Innovation Partners platform - a select group of growers with exclusive access to Arcadia's team of breeders, geneticists and computation biologists, as well as the company's seed catalog of cutting-edge new hemp varieties.

08:03 EDT PSS Industrial Group names Robert Workman as CEO - PSS Industrial Group announced that Robert Workman has been named CEO and a member of the Board of Directors, effective immediately. Robert Workman was President, CEO & Director of DistributionNOW (DNOW) from 2014 to 2019, a spinoff that he led of the Distribution Services business unit at National Oilwell Varco (NOV).

07:52 EDT Zai Lab expects to submit two IND applications in 2020 - Research facilities located in Menlo Park, California scheduled to open in mid-2020

07:51 EDT Zai Lab expects to initiate trial of INCMGA0012 in endometrial cancer in 2H20 - Enroll first Chinese patient into the Incyte-sponsored global Phase 3 study of INCMGA0012 with platinum-based chemotherapy in first-line metastatic squamous and non-squamous non-small cell lung cancer in China in second half of 2020

07:49 EDT Zai Lab expects to enroll first patient in Phase 3 ATTACK trial in 1H20

07:48 EDT Zai Lab announces expected milestones for Ripretinib - Submit NDA to the China NMPA for advanced GIST in 2020; Initiate bridging trial for second-line GIST in second half of 2020.

07:47 EDT Zai Lab announces expected milestones for ZEJULA - The company said, "Initiate registrational bridging trial for late-line ovarian cancer treatment in second half of 2020; Expect final clinical data from the NORA study, the pivotal trial for maintenance therapy of Chinese patients with recurrent ovarian cancer in first half of 2020; Continue to collaborate with our Partner GSK on additional indications and opportunities."

07:42 EDT Plus Products announces employee equity incentivization restructure - The company said, "We operate in a market that has seen industry indices lose 75% of their value since our Initial Public Offering a year-and-a-half ago. This market environment creates a challenge in talent retention for public and private companies alike. We believe that we have recruited and retained an incredible team here at PLUS. As we face a crucial year for our organization, it is important that our employees are highly motivated to increase sales and market share while pursuing profitability. To help ensure that this objective is met, we are restructuring certain previously granted equity incentives. The restructuring process will involve a forfeiture and, following the lapse of all statutory waiting periods, subsequent issuance of new awards to employees holding equity incentives that have been impacted by the market movements. All of which will be conducted in accordance with the terms of PLUS's Equity Incentive Plan. PLUS, along with our Board of Directors, has taken many steps to structure a good-faith plan consistent with our Equity Incentive Plan mandate to "promote the interests of the Company and its shareholders by aiding the Company in attracting and retaining employees." Key elements of this equity incentive restructure include the following: No member of the Board of Directors, including the Chief Executive Officer, will be eligible for participation in the restructuring effort. Equity incentives awarded to executive officers as a part of this restructuring will total 6% of the equity incentives issued as a part of this effort and 1% of the total Equity Incentive Plan pool. The equity incentives issued following the proposed forfeiture will not exceed 65% of the total forfeited equity incentives. 50% of the equity incentives issued following the proposed forfeiture will be subject to performance targets tied to PLUS's revenue growth and profitability. Following the equity incentive restructure and issuances in exchange for salary reductions of the PLUS executive management team discussed above, the total equity incentives issued and outstanding from the Equity Incentive Plan will be equivalent to 7.5% of the outstanding shares of the Company. This accounts for one-half of the 15% available to be awarded under the terms of the Equity Incentive Plan. We firmly believe this equity incentive restructuring plan is in the best interest of our current shareholders, and will ensure that existing and future employees of PLUS are properly incentivized and aligned with all of the Company's stakeholders."

07:40 EDT Plus Products says CRO Marc Seguin to depart

07:38 EDT Plus Products reduced workforce by 13 employees in January - In January of this year, the Company reduced its workforce by 13 full-time employees, accounting for 20% of its non-production workforce.

07:36 EDT JinkoSolar buys 200,000 ADSs under its share repurchase program - JinkoSolar repurchased an aggregate of 200,000 ADSs between March 17 and March 18, pursuant to the share repurchase program previously announced on March 12. JinkoSolar plans to continue to repurchase additional ADSs pursuant to this share repurchase program. Under this share repurchase program, JinkoSolar is authorized to repurchase up to $100M of its ordinary shares represented by ADSs within the twelve months following March 12.

07:35 EDT Marinus Pharmaceuticals appoints Sasha Damouni Ellis as VP, investor relations - Marinus Pharmaceuticals (MRNS) announced the appointment of Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications, reporting to Scott Braunstein, M.D., CEO of Marinus. In this role, Damouni Ellis will lead strategic investor relations and communications programs, and will work closely with investors, employees, advocacy groups, patient organizations and the media. Immediately prior to joining the company, Damouni Ellis was Director of External Communications and Media Relations for Bayer U.S. (BAYRY).

07:31 EDT Global Eagle says 'too early' to quantify COVID-19 impact - The company said, "Due to limited data, it is too early to quantify the impact of the COVID-19 outbreak on the travel industry, Company operations or our financial performance. The majority of the Company's revenue is derived from a monthly recurring charge structure rather than a usage-based structure. However, given the probable impact on global airlines and cruise lines, management is accelerating Phase III costs initiatives, including developing more aggressive plans should the impact from COVID-19 on aviation and maritime increase. In addition, management is in the process of modifying business continuity plans for the current circumstances. We remain focused on working with our partners across all verticals to serve their needs in a dynamic environment. We expect to provide more information as additional data becomes available and the impact on our business becomes clearer."

07:28 EDT Global Eagle 'on track' for second half installations for Turkish Airlines - The company said, "Global Eagle's Connectivity segment is a leading provider of satellite-based connectivity and live television programming to aviation, maritime, enterprise and government markets. Connectivity segment revenue was up 3.3% year-over-year despite the impact of the Boeing 737 MAX grounding as discussed below. Inflight connectivity installations and activations continue at Air France, powered by Global Eagle's Ku high-throughput satellite network. We operate the first EMEA HTS inflight connectivity network to provide consistent coverage and up to 500 Mbps throughput in Europe, Russia, Scandinavia, and North Africa. The Company remains on track for second half installations for our previously announced new connectivity customer, Turkish Airlines. "

07:26 EDT Aramark comments on potential COVID-19 impact - The company said, "At this stage, it is too early to determine the full impact of COVID-19 on our operational results. In general, the Company believes revenue declines would have a drop through of approximately 15%-20% on operating income due to the flexible cost structure of the business model, geographic mix and diversified client portfolio. The Sports & Leisure and Business & Industry lines of business generally have mid-single digit operating margins, while Healthcare, Education, Corrections, and Facilities & Other generally have high-single digit operating margins. In all business segments, we are leveraging our flexible operating model to execute cost mitigation plans while continuing to support our clients. The Company has a strong balance sheet with solid financial flexibility and no significant debt maturities due until 2023. Liquidity remains strong and in order to maintain maximum flexibility, the Company has decided to fully draw down on its revolver, increasing cash availability to $1.3 billion. The Company also has flexibility to optimize working capital and defer capital expenditures as appropriate without material impact. There continues to be ample room on the Company's debt covenants. At the end of the first quarter, Aramark's ratio of secured debt to Covenant Adjusted EBITDA was 2.07x on a trailing twelve-month basis - adjusted for a recent $900 million refinancing, the pro forma ratio is 2.62x, significantly under the 5.125x covenant requirement. Aramark's interest coverage ratio of 4.94x is well in excess of the incurrence covenant's 2.0x requirement. We do not anticipate accessing the credit markets in the foreseeable future. Seasonality and the sensitivity of working capital balances to the day of the pay cycle on which the quarter closes (payroll is a very large component of working capital) can cause Free Cash Flow and leverage levels to fluctuate. Due to these effects and consistent with our normal seasonality, our Free Cash Flow during our first quarter was negative $405 million. The normal-course unwinding of working capital over the remainder of our fiscal year ordinarily leads to stronger Free Cash Flow during those quarters. Concerning seasonality, we note that the early closure of an Education client would impact only a modest number of weeks of Free Cash Flow and earnings between now and September, as these units are normally shuttered over the summer. COVID-19 is creating personal and economic disruption globally. During this challenging time, we are working hard to do our part to help our employees, clients and customers stay safe. Our contribution - delivering meals, laundered uniforms and facility services to a world-class standard of hygiene and safety - is an essential component of making our society less vulnerable to disease, and ensuring that our employees and everyone we serve are safe."

07:24 EDT HighPoint Resources provides update to 2020 development program - HighPoint Resources Corporation announced an update to its 2020 development program, liquidity and hedges. Today's update takes into account the recent significant decrease in crude oil prices, and includes the following: All drilling and completion activity that is currently in progress will be completed, and all new planned activity will be deferred; this will not impact first half of 2020 production volumes; Maintain flexibility to adjust capital program further based on market conditions; Strong hedge position protects 2020 cash flow and has a current mark-to-market value of approximately $225 million; Still anticipate generating positive free cash flow in 2020; Anticipate reducing bank debt by approximately $45 million during the first quarter of 2020 and have no significant debt maturity before October 2022. CEO and President Scot Woodall commented, "Given the rapidly changing dynamics of crude oil prices our top priority is to preserve our balance sheet and liquidity in this lower crude price environment. As such, we have prudently decided to defer any new drilling and completion activity as we continue to monitor the present market environment. Although our hedge portfolio protects the returns of our 2020 investment program, we have elected to slow down activity and preserve liquidity. While this impacts near-term development activity, it is not expected to adversely affect anticipated production volumes for the first half of the year and will maintain our opportunity set for future development. Moreover, we are well positioned financially with a strong hedge portfolio covering over 90% of anticipated 2020 oil volumes at a WTI price of approximately $58.00 per barrel with an estimated mark-to-market value of approximately $225 million based on current WTI strip prices." The Company's current liquidity position is approximately $370 million. This is an increase of approximately $35 million from December 31, 2019, as the Company has reduced borrowings on its credit facility to approximately $115 million with a further reduction of approximately $20 million anticipated by the end of the first quarter of 2020.

07:22 EDT Enthusiast Gaming signs exclusive representation agreement with MCPE DL - Enthusiast Gaming announcef that it has signed an exclusive representation agreement with MCPE DL, one of the largest Minecraft online communities in the world. MCPE DL, is a leading Minecraft independent online destination, dedicated to Minecraft fans that provides downloadable content, including quality add-ons, maps, mods, and texture packs for the popular video game. Currently, MCPE DL generates, on average, 28M page views with 4.5M visitors on a monthly basis. The addition of MCPE DL to Enthusiast Gaming's network increases total monthly site viewership by almost 5%, and is now one of the largest communities across the media platform.

07:21 EDT US Ecology says currently providing COVID-19 decontamination services - US Ecology in response to the COVID-19 Coronavirus outbreak, offers a comprehensive range of decontamination response and disposal services to customers, providing safe solutions for all disinfecting and decontamination needs to combat the spread of COVID-19. The company said, "US Ecology's highly-trained professionals are currently providing COVID-19 decontamination services for a wide range of customers including retail establishments, government agencies, cruise lines, restaurants, as well as insurance, transportation and other companies across the country. The Company's experts safely handle hazardous materials and infectious waste streams on a daily basis while performing many services, and have extensive experience with managing decontamination responses to biohazards and infectious disease outbreaks with the current COVD-19 outbreak as well Ebola, H1N1 and other past health crises. US Ecology's broad range of decontamination services include biological and infectious response, cleanup and disposal, blood borne pathogen cleanup and infectious waste management. US Ecology's decontamination procedures meet or exceed the recommendations and work practices established by the Center for Disease Control, Occupational Safety and Health Administration, World Health Organization and other agencies. At each site, crew members follow stringent protocols to establish highly defined and controlled support, entry, decontamination and hot zones to ensure the safe entry/exit of response personnel and the protection of non-response personnel from affected areas. Decontamination procedures are executed by highly-trained personnel wearing the highest-grade personal protective equipment and using only approved and highly effective hospital-grade disinfecting agents."

07:17 EDT Lifeboat Distribution awarded CMAS to enable vendors, resellers reach - Lifeboat Distribution, a subsidiary of Wayside Technology Group, announced that it has been awarded a California Multiple Awards Schedule. Lifeboat will utilize its CMAS contract to promote its vendor partners while allowing its reseller customer base access to California state and local governments. The addition of CMAS allows reseller partners to market and sell products and solutions into state and local government organizations. Lifeboat focuses on high-demand and emerging technology categories such as virtualization & cloud, storage & HCI, security, data management, connectivity and software & application lifecycle. This addition also allows Lifeboat's authorized resellers to participate in the cooperative purchasing agreement with qualifying states.

07:16 EDT BioXcel says on track to report data from SERENITY trials in mid-2020 - BioXcel Therapeutics announced that more than one-third of the patients in the Phase 3 SERENITY trials have been enrolled and treated. To date, the company has not observed a change in enrollment rates resulting from the COVID-19 pandemic, and currently maintains previous guidance that SERENITY I & II are expected to be completed by mid-year 2020. The SERENITY studies are randomized, double-blinded, placebo-controlled, adaptive trials of up to 750 patients, 18 to 75 years of age. SERENITY I is enrolling patients with agitation associated with schizophrenia, with each arm receiving BXCL501 at 120 micrograms, 180 micrograms or placebo, respectively. SERENITY II is evaluating patients with agitation associated with bipolar disorder, also in three arms receiving BXCL501 at 120 micrograms, 180 micrograms or placebo, respectively. The primary endpoint of the trials is reducing acute agitation measured by the Positive and Negative Syndrome Scale, examining the Excited Component (change from baseline compared to placebo. A key secondary endpoint includes determining the earliest time where an effect on agitation is apparent as measured by the change from baseline in PEC total score.

07:14 EDT Applied DNA Sciences completes design of diagnostic kit for SARS-CoV-2 - Applied DNA Sciences announced the completion of design of a diagnostic kit for SARS-CoV-2 being developed for production via the company's proprietary PCR-based DNA, or LinearDNA, manufacturing process. The company's announcement follows its statement on March 2, updating their collaborative progress with Takis Biotech, in Rome, Italy, on a series of LinearDNA vaccine candidates against the Spike protein of SARS-CoV-2. The announcement highlighted that the preclinical trials for the jointly developed vaccines have been authorized by the Italian Ministry of Health, and are the first trials in Italy to have reached this stage. Applied DNA makes clear that no commercial partner has been identified to take the developmental diagnostic to market, nor is there any indication that the company's diagnostics would be approved by regulators. The assay will use the Applied Biosystems 7500 Fast Dx Real Time PCR instrument, widely deployed in diagnostic labs and hospitals the world over. Once fully validated and ready for shipment, the company plans to sell the diagnostic kit as "For Research Use only" while awaiting the potential Emergency Use Authorization by FDA, which would empower sales to diagnostic labs.

07:10 EDT Hookipa Pharma says on track to file HB-202 initial new drug submission in 1H20 - HB-201 and HB-202, HOOKIPA's TheraT-based lead oncology product candidates, are in development for the treatment of Human Papillomavirus serotype 16-positive cancers. HOOKIPA dosed the first patient in an open label, dose escalating Phase 1/2 clinical trial for HB-201 in December 2019, HOOKIPA's first clinical trial in immuno-oncology. The Company expects preliminary results in late 2020 or early 2021. HOOKIPA's second planned Phase 1/2 clinical trial will assess the safety and efficacy of the combination of HB-201 and HB-202 in HPV16+ cancers, with or without an approved checkpoint inhibitor. HOOKIPA remains on track to file the HB-202 Initial New Drug submission with the U.S. Food and Drug Administration in the first half 2020. The planned HB-202/201 clinical trial is an open label, dose escalation Phase 1/2 trial with the primary endpoint to evaluate safety and tolerability. That trial is expected to commence later in 2020.

07:09 EDT Rocket Pharmaceuticals announces publication of LAMP2B study data - Rocket Pharmaceuticals announced the peer-reviewed publication of a study evaluating the efficacy of an adeno-associated virus, or AAV-based gene therapy delivering human LAMP2B in a mouse model of Danon Disease, a rare genetic disorder often resulting in heart failure. The Science Translational Medicine publication describes data demonstrating that vector-mediated transfer of LAMP2B to deficient mice improved heart function and survival. These findings underscore the promise of Rocket's AAV-based gene therapy candidate for Danon Disease, RP-A501. In this study, researchers evaluated the efficacy of a single intravenous, or IV, infusion of recombinant adeno-associated serotype nine capsid containing the human LAMP2B transgene, or AAV9.LAMP2B, in LAMP2-deficient mice, an established model of Danon Disease. Two cohorts of male mice, aged two- or six-months-old, were treated with four separate dose levels of AAV9.LAMP2B to determine the therapeutic potential of this gene therapy to prevent the development of or reverse an established disease phenotype. Rocket is currently investigating RP-A501 as a treatment for Danon Disease in an ongoing Phase 1 dose escalation study. The trial is enrolling 12-24 pediatric and young adult male patients to assess the short and long-term safety and efficacy of increasing dose levels of RP-A501 in pediatric and adult cohorts. UC San Diego Health is the lead center for the clinical trial.

07:06 EDT VBL Therapeutics expects pre-IND submission for VB-601 in 2Q20 - MOSPD2 mAb program for inflammation - VBL continues to advance the development of lead MOSPD2 antibodies for immune-inflammatory indications, with potential for MS, RA and NASH. The Company signed a service agreement with Thermo Fisher Scientific, one of the leading vendors in the antibody field, for production of lead candidate VB-601 for toxicology and clinical development. A pre-IND submission for VB-601 is expected in 2Q 2020. New data on MOSPD2 as a target for inflammatory digestive disorders were accepted for presentation at EASL's annual International Liver Congress, ILC 2020, and Digestive Disease Week conferences later this year. Our abstract for DDW was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction.

07:05 EDT Darden reports Q3 blended same-restaurant sales up 2.3% - Q3 same-restaurant sales by brand: +2.1% for Olive Garden; -1.6% for Cheddar's Scratch Kitchen; +3.9% for LongHorn Steakhouse; +1.8% for Yard House; +4.2% for The Capital Grille; +3.0% for Seasons 52; +3.9% for Eddie V's; -0.5% for Bahama Breeze.

07:04 EDT VBL Therapeutics expects interim analysis of OVAL Phase 3 study in 1Q20 - VB-111 program in ovarian cancer - The OVAL Phase 3 potential-registration study of VB-111 in ovarian cancer continues as planned towards the important interim analysis in 1Q 2020. This analysis will focus on CA-125 response rate, which will be analyzed according to GCIG strict criteria in 60 evaluable patients. The data will help to inform whether the positive outcome observed with VB-111 in the Phase 2 study in ovarian cancer is being replicated in the OVAL Phase 3 trial. Results from a Phase 1/2 clinical trial of VB-111 in the treatment of patients with recurrent platinum resistant ovarian cancer were presented at the 2019 American Society of Clinical Oncology annual meeting. Data demonstrated a median overall survival of 498 days in the VB-111 therapeutic-dose arm, versus 172.5 days in the low-dose arm. 58% of evaluable patients treated with the therapeutic dose of VB-111 had a GCIG CA-125 response. In comparison, in the AURELIA trial, the GCIG CA-125 response rate was 31.8% with bevacizumab and chemotherapy, and only 11.6% with chemotherapy alone.

07:02 EDT Bellus Health completes enrollment in Phase 2 RELIEF trial of BLU-5937 - Bellus Health announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients with refractory chronic cough.

07:01 EDT GE Healthcare CEO issues statement regarding COVID-19 - GE Healthcare President & CEO Kieran Murphy issued the following statement around efforts to address the coronavirus (COVID-19): "GE Healthcare is proud to support customers, governments and the broader healthcare community in the fight against the coronavirus. Our dedicated teams are working around the clock to ensure that our customers and partners on the front lines have the equipment and servicing needed to diagnose and treat patients with COVID-19. To help address this global challenge, we have increased our manufacturing capacity and output of equipment - including CTs, ultrasound devices, mobile X-ray systems, patient monitors and ventilators - important in the diagnosis and treatment of COVID-19 patients, while taking steps to ensure safe operations for our employees. As the global pandemic evolves, there is unprecedented demand for medical equipment, including ventilators. We continue to explore all options to support this increased need. Direct actions we are taking include: Adding manufacturing lines to ventilator production and increasing the number of shifts to produce around the clock; Hiring additional manufacturing employees and shifting current employees to support increased demand immediately; Managing our supply chain by working with suppliers to mitigate shortages and minimize impact on our customers globally; Partnering with global regulators and using our clinical and technical expertise to urgently address questions from customers on how to meet patient needs; Monitoring the health of our field service engineers and providing personal protective equipment for them when servicing devices - as well as increasing remote diagnostic and repair capabilities. "As we continue to support our customers and partners, the health and safety of our employees remains our top priority. I am deeply proud of the work the GE Healthcare team is doing to tackle this global challenge."

06:59 EDT Comstock Mining provides 2020 outlook - Comstock Mining expects to close on the agreed upon sale of certain non-mining assets located in Silver Springs, NV, to Sierra Springs Enterprises during the first half of 2020, for total net proceeds of $10.1M. The agreements were signed during 2019, with $0.3M of non-refundable deposits made and released to the company from escrow. The company will use the remaining $9.8M of proceeds to extinguish the entirety of its outstanding Senior Secured Debenture obligation, principal and make-whole of approximately $4.9M, plus accrued interest of approximately $0.3M. During 2020, the company expects to receive a total of approximately $2.3M in cash for expense reimbursements required under the various Tonogold agreements. The company's annual operating expenses, including other income and expenses and excluding depreciation, are planned to be $4.9M for fiscal year 2020, with approximately $2.3M of that amount currently being reimbursed under the various Tonogold agreements, resulting in 2020 net operating expenses of $2.6M.

06:56 EDT Devon Energy provides hedge position update - Devon Energy provided an update regarding its oil and natural gas hedge position. The company has approximately 80% of its estimated oil production in 2020 protected at an average floor price of nearly $45 WTI. Additionally, Devon has secured hedges on approximately 40% of its estimated natural gas production in 2020 at an average Henry Hub protected floor price of $2.35 per million cubic feet. The company's hedge position is composed of swaps and costless collars, with no pricing downside from three-way collars. The estimated market value of the company's hedge position in 2020 is approximately $800M based on the current WTI and Henry Hub strip price. Devon continues to dynamically manage its hedge position to provide additional protection against lower commodity prices through 2021. This risk-management program consists of systematic hedges added on a rolling six-quarter basis and discretionary hedges that take advantage of market opportunities. "Given the high degree of uncertainty associated with this unprecedented pricing downturn, we have taken decisive actions through our hedging program to protect our balance sheet, preserve liquidity and support our dividend," said Dave Hager, president and CEO. "This advantaged hedge position, combined with our high-quality asset base and excellent liquidity, positions Devon to effectively navigate through this period of extreme commodity price volatility."

06:51 EDT GP Strategies continues providing health preparedness services during COVID-19 - As cases of COVID-19 rise in the United States, global workforce transformation solutions provider GP Strategies is working inside public organizations to minimize the impact of the virus on personnel safety, business continuity, and productivity. GP Strategies has decades of experience providing strategic project management and emergency planning, training, exercise-support, and staff augmentation solutions to organizations and public health institutions across the country. These services cover the scope of public emergencies, including terrorism, natural disasters, and pandemic outbreaks, including influenza-specific occurrences such as the past H1N1 pandemic crisis. During the COVID-19 outbreak, GP Strategies is increasing their level of support with customers, helping to staff call centers, ensuring preparedness plans are being followed, and offering readiness assistance.

06:50 EDT Accenture reports Q2 new bookings $14.2B - Includes consulting bookings of $7.2B and outsourcing bookings of $7B.

06:46 EDT Tailored Brands closing e-commerce centers and retail stores through March 28 - Tailored Brands will close its e-commerce fulfillment centers starting Friday, March 20 through at least Saturday, March 28, and will suspend the currently limited operations in its retail stores during this period. All employees will be paid for scheduled hours throughout this time period. Customers can continue to place orders online to be shipped after the distribution center reopens. The company will continue to provide updates and re-evaluate this rapidly changing situation as it evolves.

06:44 EDT Accenture raises quarterly dividend 10% to 80c per share

06:33 EDT Thomson Reuters acquires Pondera Solutions, terms not disclosed - Thomson Reuters announced that it has acquired Pondera Solutions, a leading provider of technology and advanced analytics to combat fraud, waste and abuse in healthcare and large government programs. Thomson Reuters serves government agencies at the federal, state and local level with solutions and resources to improve efficiencies, diminish risk and reduce fraud. The acquisition of Pondera Solutions will enhance the offerings in the risk, fraud and compliance space and will allow Thomson Reuters to expand on its strategic approach to deliver insight through advanced analytics, artificial intelligence and human expertise. Financial terms of the acquisition were not disclosed.

06:33 EDT Co-Diagnostics JV CoSara receives license to manufacture COVID-19 test kits - Co-Diagnostics announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing in India, has become the first and only Indian company to receive a license from the Central Drugs Standards Control Organisation to manufacture RT-PCR COVID-19 test kits. The kits are expected to be sold in the Indian market, as well as for export to the surrounding regions. CoSara has aligned itself with the "Make in India" initiative introduced in 2014 to transform India into a global design and manufacturing hub, and senior officials from the health department expedited the approval process for the license. The country took early measures to recall its citizens, drastically limit travel into the country and eventually close the country's borders, which has also increased the demand for indigenous COVID-19 tests to serve India's population of 1.3B.

06:15 EDT Diamondback Energy further reduces 2020 capital budget - Diamondback Energy provided an update to the operational press release it issued on March 9, as well as an update to the company's 2020 and 2021 oil hedge positions. Diamondback has reduced activity further, including a minimum one-month break for all completion crews operating for the company. After that break, the company expects to reactivate crews and run between three and five completion crews, down from nine crews, for the rest of 2020 dependent upon future commodity price, with the primary goal of protecting the company's balance sheet and cash flow. Diamondback plans to reduce its operated drilling rig count to ten by early in Q3 as contracts roll off over the next few months, and plans to run between six and ten rigs thereafter dependent upon future commodity price, representing more than a 50% reduction in rigs from earlier this year. As a result of this reduction in activity, the company is expected to reduce its capital budget for 2020 by $1.2B at the midpoint to $1.5B-$1.9B from its previously announced $2.8B-$3.0B capital budget, and is prepared to decrease its budget further should commodity prices remain weak. The company's 2020 infrastructure budget will be reduced to $90M-$120M from the $150M-$175M previously announced. The company's midstream budget will be reduced to $100M-$150M from the $200M-$225M previously announced. The company intends to release revised production guidance in the coming weeks, but expects production to decline from Q1 through the end of the year, with full year oil production lower than 4Q19 oil production of 195K barrels per day. "We are in an unprecedented and uncertain market driven by fear and panic. In this environment where we do not get paid adequately for the product we produce, we will reduce activity and focus on maintaining our financial strength. Diamondback is protecting its downside by hedging almost all of its expected 2020 production and has added significant hedges for 2021 since our last update ten days ago. We are pulling out our 2016 playbook by high-grading locations to where we have mineral ownership through Viper and minimal midstream and infrastructure capital requirements, and have shifted over 70% of our planned future activity to the Midland Basin, where we have better returns through our cost structure," stated CEO of Diamondback Travis Stice . "(...) Our consolidated cash interest expense is $220M per year and our cash general and administrative expense is ~$80M per year, with all other costs on the table for removal or further reduction, including lease operating expenses and all capital. We have reduced activity dramatically and swiftly, and are prepared to reduce it further for an extended period of time." The company now has a total of 148.8 thousand barrels per day protected in 2020, with 91% of those hedges having unlimited downside protection as a swap, put or collar. The company has added 73.5 thousand barrels per day of hedges in 2021 through a combination of collars and swaps.

06:12 EDT Soligenix announces preliminary Phase 3 FLASH trial results - Soligenix announced preliminary top-line results for its pivotal Phase 3 FLASH trial evaluating SGX301 in the treatment of cutaneous T-cell lymphoma, or CTCL. The study enrolled 169 patients randomized 2:1 to receive either SGX301 or placebo, demonstrating statistically significant treatment response in the Composite Assessment of Index Lesion Score, or CAILS, primary endpoint assessment at 8 weeks for Cycle 1. In addition, preliminary assessment of the open-label Cycle 2 results suggest a more robust response rate after 12 weeks of SGX301 treatment. These data are expected to be announced in June. The company will share trial results during an investor conference call. "This is an important outcome for patients suffering from CTCL. SGX301 has successfully demonstrated efficacy in this challenging chronic cancer, with no safety concerns, making it a potentially preferred first-line option for the treatment of early stage CTCL, which is the large majority of patients suffering from this disease," stated Ellen Kim, Director of the Dermatology Clinic, Perelman Center for Advanced Medicine and Lead Investigator of the FLASH study. "The treatment showed a statistically significant improvement after just 6 weeks of treatment. This successfully proves that the drug has biologic activity in combating this disease in a relatively short time window, with preliminary data suggesting that the improvement continues to increase with extended treatment. In addition to the efficacy demonstrated, SGX301 was well-tolerated and its mechanism of action is not associated with DNA damage like other currently available therapies."

06:08 EDT Viper Energy provides update on 2020 production guidance - Viper Energy is updating its average daily production guidance for 2020 to 14K-17K bo/d - 22,500-27,000 boe/d -. This guidance reflects the company's current estimated production given Diamondback's updated development plans and contemplates only limited contribution from further development by third-party operators. The Board of Directors of Viper's general partner authorized the company to hedge a majority of its 2020 and 2021 estimated oil production primarily through WTI collars to limit downside to the company's cash flow. "Viper is reducing production expectations for the year due to significantly lower expected activity levels on third-party operated properties and slightly lower activity levels from Diamondback. Times like these emphasize the value of the Diamondback and Viper relationship, as Diamondback has focused its drilling on areas where Viper's mineral ownership lowers consolidated breakeven economics. Viper has also now hedged the majority of its production, primarily through collars, to protect cash flow downside through an anticipated weak commodity price environment for an extended period of time," stated CEO Travis Stice.

06:08 EDT Lennar up 2.5% after reporting Q1 results

06:06 EDT Lennar reports Q1 backlog up 2% to 17,632 homes - Reports Q1 backlog dollar value up 1% to $7.2B.

06:05 EDT Lennar reports Q1 backlog up 2% to 17,632 homes - Reports Q1 backlog dollar value up 20% to $7.2B.

06:05 EDT Armada Hoffler provides development pipeline update - Armada Hoffler provided an update on the projects currently under development. The company announced that it will be deferring the previously announced Chronicle Mill, Southern Post, and Ten Tryon development projects until economic conditions stabilize. Each of these projects had previously been scheduled to commence during the second quarter. The company also announced that both Summit Place and Wills Wharf remain on schedule for delivery in 2020 as previously disclosed with sufficient construction loan commitments to fund the remaining estimated costs to complete. "Our Company was built to withstand uncertainty and volatility," said Louis Haddad, President and CEO of Armada Hoffler Properties. "The flexibility afforded by our diversified business model allows us to quickly adapt to changing market conditions. Therefore, we will be deferring several of our development projects until economic conditions normalize, thereby alleviating any near-term need for additional capital. As a result, we have indefinitely suspended all capital markets activity through our ATM program. With ample construction loan commitments in hand, we look forward to delivering both Wills Wharf and Summit Place this year as scheduled." Haddad continued, "While it's impossible to predict how long current conditions will last, the fundamentals of our business remain strong. As this company's largest shareholder, management is committed to prudent and conservative capital allocation in order to maximize value for all shareholders. The impact of the coronavirus pandemic on the global economy and our business remains uncertain and is evolving rapidly, and we intend to provide additional updates to our shareholders as conditions merit." Management expects to provide an update on its outlook and guidance for 2020 in conjunction with the release of its first quarter earnings on April 30.

05:53 EDT Autoliv takes steps to mitigate impact of COVID-19, draws $500M from credit - Autoliv, announced that the coronavirus (COVID-19) outbreak will likely lead to a negative effect on the company's operations due to how the outbreak is affecting the automotive industry in general. The extent of such negative impact remains to be seen. Autoliv has tapped $500 million from its revolving credit facility to pay down existing short-term debt and for general corporate purposes. Autoliv is continuously monitoring the evolving COVID-19 pandemic and proactively taking measures to minimize any consequences for customers and mitigate the impact on the company. "The COVID-19 outbreak is now impacting our customers in Europe and this week there have been several announcements by our customers of plant closures in e.g. France, Italy, Spain and Germany. Based on our most recent information from our customers, media and other sources, we estimate that 63 customer plants in Europe will close or have already closed. A number of our customers announced late yesterday shut down of all plants in the U.S. as well as closures in other countries. How long these plants will be closed, or to what extent more will follow is highly uncertain. In light of these events, we are taking cost reduction actions to mitigate the impacts and Autoliv will adjust its production in accordance with the development of the demand situation, and it cannot be excluded that temporary Autoliv plant closures may become necessary. Management focus is currently on strategic planning for various scenarios, which includes the potential there is a significant decline in light vehicle demand. In the event of such scenarios, the company will take corresponding actions. At this point, it is impossible to predict the overall operational and financial impact this pandemic will have on Autoliv although it will likely to lead to negative effects on our operations. Our actions to mitigate the effects of lower business activity include expanding our existing structural efficiency program, balancing our labor force and the sourcing of direct materials, reducing discretionary spending and securing funding availability to support our business activities. Additionally, today we have drawn down $500 million of our existing committed $1.1 billion Revolving Credit Facility. The Facility is with 14 international banks and matures in July 2023. The company intends to use $300 million of the draw down to pay existing short-term debt maturities for the next three months. We plan to use the remaining amounts for general corporate purposes. The remaining $600 million of the Facility is still available to the company for further potential drawdown. The availability of the Facility is not subject to any financial covenants nor is any other substantial financing of Autoliv subject to any financial covenants. For the remainder of 2020, the company's only major debt maturity is EUR 100 million in December. Since early February, Autoliv has been taking decisive actions at both the group and local levels to mitigate the impacts of the COVID-19 outbreak, firstly to ensure the health and wellbeing of our employees but also to establish the right balance of capacity and cost. We have been able to secure a well-functioning supply chain so far, and our operations in China have gradually recovered over the past few weeks, and is well tuned to customer demand as it gradually recovers. "I feel confident we have the experience, organization and people to navigate through this challenging situation" said Mikael Bratt, President and CEO. "Our task force for different workstreams, that initially was set up in January to manage the COVID-19 outbreak in China and later in South Korea and Japan, is now managing the situation on a global level, which has allowed us to act promptly as the situation continues to develop."

05:43 EDT Genentech initiates Phase III clinical trial of Actemra - Genentech, a member of the Roche Group, announced that the company is working with the FDA to initiate a randomized, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority, or BARDA, a part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, or ASPR, to evaluate the safety and efficacy of Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care. This is the first global study of Actemra in this setting and is expected to begin enrolling as soon as possible in early April with a target of approximately 330 patients globally, including the United States. The primary and secondary endpoints include clinical status, mortality, mechanical ventilation and intensive care unit variables. To date, there are several independent clinical trials exploring the efficacy and safety of Actemra for the treatment of patients with COVID-19 pneumonia. Actemra has been included in the 7th updated diagnosis and treatment plan for COVID-19 issued by China's National Health Commission, or NHC on March 3. However, this new trial is vital because there are no well-controlled studies and limited published evidence on the safety or efficacy of Actemra in the treatment of patients suffering from COVID-19. In addition, Actemra is not currently approved for this use by any health authorities, including the FDA. In addition to initiating this trial, Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 Test on March 13, 2020, to detect the novel virus that causes COVID-19 disease.

05:26 EDT B2Gold announces COVID-19 response plan - B2Gold has been monitoring the COVID-19 outbreak and the potential impact at B2Gold's operations since mid-February and, as such, has put measures in place and introduced additional precautionary steps to manage and respond to the risks associated with COVID-19 to ensure the safety of our employees and surrounding communities where we work while continuing to operate. All B2Gold corporate personnel travel has been restricted to absolute minimum requirements and employees in the corporate offices have been encouraged to work remotely. At each of our mines in Mali, Namibia and the Philippines, and at our development project in Colombia, we have implemented several control measures for dealing with the outbreak of COVID-19. These include pre-screening for symptoms and travel history with possible COVID-19 exposure of any employees, visitors and contractors (site personnel) prior to any travel to or from a site and isolation, where necessary, from the general site population. Each site has implemented restrictions and isolation procedures that are particular to each region's situation and response capabilities. Procedures continue to evolve according to the World Health Organization and Center for Disease Control guidelines as more becomes known about the virus. The company is regularly monitoring the situation and following local and national health authority requirements and recommendations. A critical care specialist has been consulting the Company on the guidelines and global implementation. To date, B2Gold has not experienced any incidents related to COVID-19 at its sites or corporate offices and continues to operate all mine facilities and is proceeding with its projects as previously planned. The mill expansion and solar facility projects at the Fekola Mine in Mali are still projected for completion in the third quarter of 2020, the Gramalote Project in Colombia continues to drill off the Inferred Mineral Resource and progress its feasibility study, and development of the underground mine at Otjikoto in Namibia is moving forward. The Company does not expect material delays in the current schedules, but will continue to monitor the situation, seek advice from specialists where required and adjust plans, if necessary, to adapt to the ever-changing landscape. B2Gold continues to engage with local stakeholders to prevent the virus from entering the communities around our operations. Education programs are being put into place to protect the communities by promoting hygienic practices and limit social interactions in an effort to prevent the spread of the virus.